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INTRODUCTION 
Developmental appearance of GH- and PRL-secretina cell types 
Until recently, it was generally accepted that growth 
hormone (GH) and prolactin (PRL) were secreted by separate 
and distinct cell types within the anterior lobe of the pi­
tuitary gland. However, by employing reverse hemolytic 
plaque assays (RHPAs) that enable detection of hormone 
release from individual cells, Frawley et (l) have 
identified individual pituitary cells from rats which simul­
taneously release both GH and PRL. The dual hormone-releas­
ing cells were found to be present in appreciable numbers 
(one third of all cells) in pituitaries from adult male 
rats, and were designated mammosomatotropes. In light of 
this observation, the objective of the first part of this 
dissertation was to investigate the possibility that mammo­
somatotropes might be developmental intermediate cell types 
which eventually give rise to classical mammotropes (which 
release PRL alone) and somatotropes (which release GH only). 
Initially, RHPAs were used to more clearly delineate the de­
velopmental appearance of GH- and PRL-releasina cells. 
Similarly, immunocytochemistry was employed to assess the 
appearance of GH- and PRL-containina cells. In this manner, 
the temporal relationship between the initiation of hormone 
production and release, as well as the onset of responsive­
ness of these cells to secretagogues could be monitored. 
Subsequently, a variation of the plaque assay which enabled 
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detection of GH and PRL release from the same cells was used 
to delineate the developmental appearance of the mammosoma-
totrope cell type. 
Developmental regulation of GH- and PRL-secretinq cell 
populations 
The synthesis and release of adenohypophyseal hormones 
are under stimulatory and/or inhibitory control by hypothal­
amic hypophyslotropic factors (2-11). These substances are 
produced in hypothalamic neurons, enter the hypothalamo-
hypophyseal portal veins at the median eminance, and exert 
their effects on the cells of the anterior pituitary, as 
originally suggested by Harris (12). Although the acute 
effects of these factors on adenohypophyseal function have 
been characterized extensively, few studies have dealt with 
the chronic influence of these agents on cell populations of 
the anterior pituitary gland. Therefore, the RHPA was used 
to Investigate whether chronic exposure to these factors may 
regulate the size of GH and PRL cell populations during 
development. This age group was chosen for study for two 
reasons. First, day 5 is the age at which the hypothalamo-
hypophyseal portal system completes functional maturation, 
so this is the earliest age at which the hypothalamus could 
exert a major influence over pituitary function via the 
classical portal pathway (13), and cells may be particularly 
responsive to trophic agents at this time. Second, day 5 
corresponds to the day after which PRL-secreting cells first 
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appear within the pituitary gland. Inasmuch as GH cells 
precede PRL cells during development, this is the youngest 
age at which both cell types would be present. 
Age-associated differences in GH release between sexes 
Sexual differences in pituitary content (14-17) and 
release (18-22) of GH appear around the time of puberty in 
rats, when values for males exceed those of females. How­
ever, it is not known whether these differences are attribu­
table to alterations in the absolute number of GH cells, to 
changes in the amount of GH released by each cell, or to 
both. Therefore, the RHPA for GH was employed to 
distinguish between these possibilities. To this end, the 
percentages of cells which formed GH plagues as well as the 
sizes of plaques that formed (a relative index of the amount 
of hormone released) were monitored in pituitary cultures 
from rats of each sex at various stages of development. 
Inhibitory regulation of GH release 
Numerous studies have documented the ability of GH to 
regulate its own secretion through a short-loop feedback 
mechanism involving hypothalamic somatostatin (23-30). Yet, 
until recently, the existence of a long-loop feedback mech­
anism of GH release had not been identified. GH stimulates 
the production, in liver tissue, of a family of molecules 
called the somatomedins. Insulin-like growth factor-I (IGF-
I)/somatomedin C has been the most intensely characterized. 
In the last few years, several studies have demonstrated the 
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ability of IGF-I to inhibit, via a long-loop feedback 
mechanism, GH secretion (31-35). However, the dynamics of 
this inhibition have not been well defined. Although it is 
generally accepted that hypothalamic somatostatin and 
hepatic IGF-I act directly at the pituitary level to inhibit 
GH release, it is not known whether all somatotropes are 
responsive to these agents. Earlier reports have documented 
the presence of functional subpopulations among somatotropes 
in rats (1, 36-39). Such heterogeneity has been revealed 
primarily (1, 36, 37, 39) by use of reverse hemolytic plaque 
assays. Therefore, this technique was used to determine 
whether somatotropes from male rats are differentially 
responsive to somatostatin and IGF-I. 
Liver lactogenic factor 
Although GH and PRL exhibit a remarkable degree of 
overlap in both structure (40) and physiologic function 
(41), it has only recently been suggested that these 
hormones may also share a common mode of action (42). It is 
well documented that GH stimulates the liver to produce 
somatomedins which then stimulate sulfation in bone, thereby 
mediating the action of GH. To investigate the possibility 
that, like GH, PRL might stimulate the liver to produce a 
substance(s) which mediates a major component of its action, 
a reverse hemolytic plaque assay (based on the detection of 
casein release from isolated mammary cells) was utilized to 
monitor lactogenic activity of liver incubates. 
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ABSTRACT 
Immunocytochemistry (ICC) and a reverse hemolytic 
plaque assay for GH were used to investigate the temporal 
relationships between the initiation of hormone storage and 
release by developing somatotropes and the onset of respon­
siveness of these cells to stimulatory and inhibitory 
secretagogues. Anterior pituitaries obtained from rats on 
days 18-21 of fetal development (pups were generally de­
livered on fetal day 22, which is equivalent to day 0 of 
neonatal life) were monodispersed with trypsin, cultured for 
24h, and then subjected to reverse hemolytic plaque assay 
and/or ICC for GH. GH-containing cells (determined by ICC) 
were extremely rare (<1%) in cultures derived from day 18 
fetuses, but accounted for 22.4%, 25.2%, and 24.5% of all 
cells in cultures from day 19-21 fetuses, respectively. The 
proportion of GH-releasing cells, as determined in a long 
term (120-min incubation with antibody) plaque assay, was 
less than 1%, 22.4%, and 22.9% for days 18, 20, and 21, 
respectively, but only 13.6% for day 19 cells. Thus, many 
pituitary cells from day 19 fetuses contained, but did not 
release, GH, While GH-releasing factor (1-44)(IxlO^^M) had 
no effect on the percentage of GH plaque-forming cells in 
long term incubations, it enhanced (by approximately the 
same degree in day 19-21 groups) the percentage of cells 
that formed plaques and the size of the plaques in short 
term (45-min) incubations with antibody. Somatostatin 
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(IxlO'^M) exerted inhibitory effects on these variables when 
tested in long term incubations, and age of the donor rats 
did not influence pituitary responsiveness to this 
secretagogue. These results suggest that the capacities of 
fetal somatotropes to store 6H and release it under basal 
and regulated conditions are attained, in large part, within 
an extremely narrow time frame between days 18 and 19 of 
fetal development. 
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INTRODUCTION 
Considerable immunocytochemical and radioimmunological 
evidence indicates that somatotropes first appear within 
pituitaries of fetal rats during the last few days of 
gestation (1-6). However, the temporal relationships 
between the initiation of hormone production and release by 
somatotropes and the onset of responsiveness of these cells 
to secretagogues is not understood. While TRH and another 
peptide with GH-releasing activity are present within the 
hypothalamus of the fetal rat (7, 8), there are conflicting 
reports about the responsiveness of the fetal pituitary to 
hypothalamic factors known to stimulate 6H release in the 
adult (8, 9). Moreover, the effectiveness of somatostatin 
(which is also contained within the fetal hypothalamus) in 
regulating GH release from the pituitary of the fetus is 
equally controversial (8-11). 
In the present study, we investigated two aspects of 
somatotrope development; 1) the relationship between the 
onset of hormone storage and basal release; and 2) the 
attainment of responsiveness to hypothalamic regulatory 
factors. This was accomplished by using a reverse hemolytic 
plaque assay (RHPA) to identify and assess the responsive­
ness of individual GH-releasing cells in monolayer cultures 
of fetal pituitaries. In addition, we employed immunocyto-
chemistry (ICC) to detect GH-containing cells in the same 
cultures. 
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MATERIALS and METHODS 
Animals and cell culture 
Fetal animals used in this study were obtained by 
laparotomy of timed pregnant rats (Holtzman, Madison, Ml) 
which arrived at our animal facility on or before day 16 of 
gestation. The morning on which sperm was detected in 
vaginal lavage of these primiparous females was designated 
day 0 of pregnancy. All animals were maintained under 
conditions of constant temperature (23 C) and photoperiod 
(lights on from 0600-1800h) and were provided with rat chow 
(Simonsen, Quimby, IA) and tap water ad libitum. 
Anterior and neurointermediate lobes of pituitaries 
from fetal rats (sex unspecified) were separated aseptically 
in situ with the aid of a dissecting microscope. The intact 
adenohypophyses were placed in a solution of trypsin [Difco, 
Detroit, MI; 0.1%; in Eagle's Minimum Essential Medium with 
antibiotics (100 U/ml penicillin G and 100 ug/ml strepto­
mycin sulfate; Grand Island Biological Co. [GIBCO], Grand 
Island, NY) and 0.1% BSA (Sigma, St. Louis, MO)] and 
monodispersed with a modification of the method of Hymer et 
al. (12), which has been described in detail previously 
(13). The only departure from this latter procedure was 
that dispersion time was reduced to 30 min, and tissue frag­
ments were pipetted gently with a flame-polished Pasteur 
pipette at 15 min. Pituitary tissues from 40-65 fetuses 
derived from at least 4 different mothers were pooled for 
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each dispersion. Cell yields ranged from 1.45-1.73x10^ 
cells/pituitary for donors with fetal ages of 18-21 days, 
respectively. 
The dispersed cells were plated onto poly-L-lysine 
(Sigma)-coated plastic petri dishes (35mm; Falcon Plastics, 
San Francisco, CA) and cultured in Dulbecco's Modified 
Eagle's Medium (GIBCO) supplemented with 10% horse serum 
(GIBCO) and antibiotics (GIBCO) (13). Twenty-four hours 
later, cells were recovered from the petri dishes after a 
brief (10-min) incubation with a dilute (0.025%) solution of 
trypsin. The retrypsinized monodispersed cells were washed 
several times and resuspended in Dulbecco's Modified Eagle's 
Medium containing antibiotics and 0.1% BSA (henceforth 
referred to as DMEM) for use in plaque assays or ICC. 
RHPA 
The RHPA for GH, which is based on antibody-directed, 
complement-mediated lysis of sensitized indicator cells 
(erthrocytes) in the vicinity of GH-releasing cells, was 
performed essentially as described previously (14, 15), with 
minor modifications. Briefly, medium (DMEM) containing a 
suspension of protein-A-coated ovine erythrocytes (oRBCs; 
6%) and monodispersed anterior pituitary cells (7.5x10® 
cells/ml) was infused into an incubation chamber composed of 
a glass coverslip which spanned two pieces of double stick 
tape attached to the surface of a poly-L-lysine-coated 
microscope slide. The monolayer of oRBCs and pituitary 
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cells that formed over the next 45 min was washed (to remove 
unattached cells) and then Incubated for a period of 45-120 
min in the presence of Medium containing secretagogues 
[human pancreatic GH-releasing factor (1-44) (GRF); 
Peninsula Laboratories, Belmont, CA; and somatostatin, Sigma 
Chemical Co., St. Louis, MO; both at 1x10~'7m] when appro­
priate and rabbit antirat GH serum (15) at a final dilution 
of 1:160. The assay chamber was then flushed with fresh 
medium and refilled with guinea pig complement (6IBC0) at a 
dilution of 1:40 in DMEM. Plaques developed over the next 
50 min, and the reaction was terminated by infusion of a 
solution of 2% glutaraldehyde in 0.9% saline. Slides 
supporting the fixed monolayers were stored in this same 
preservative for microscopic viewing and analysis of plaques 
at a later time. 
The specificity of GH antiserum and its suitability for 
use in plaque assays was established by demonstrating that 
1) cross-reaction with PEL was not detectable in classical 
cold displacement experiments of the type routinely used to 
characterize antisera for RIA purposes; 2) radioiodinated 
PRL did not bind to GH antiserum linked to oRBCs via protein 
A, whereas radioiodinated GH did attach; and 3) preabsorp-
tion of the antibody with iodination grade GH abolished 
plaque formation in these studies, whereas treatment with 
100- to 1000-fold greater amounts of PRL did not inhibit 
plaque development. The types of controls described for 
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this study are virtually identical to those presented pre­
viously in more detail (14, 15). 
ICC 
Different batches of pituitary cells from the same 
cultures used for plague assays were applied to poly-L-
lysine-coated glass microscope slides and incubated in a 
humidified atmosphere of 95% air-5% CO2 at 37 C for 45 min. 
After attachment, the cells were washed gently with Tris-
saline buffer [TBS; 0.05M Tris (hydroxymethy1 aminomethane) 
and 0.15M sodium chloride in distilled H2O]. This and all 
subsequent washes involved flooding the slides with this 
buffer three times for 5 min each time. The monolayers were 
covered with B-5 fixative [0.25M mercuric chloride, O.IM 
sodium acetate, and 4% (final concentration) formaldehyde in 
distilled H2O] for 10 min and then incubated with the 
following solutions for 1 min each: 1) 95% ethanol, 2) 
distilled H2O, 3) Lugol's iodide (0.08M iodine and 0.12M 
potassium iodide in distilled H2O), 4) distilled H2O, 5) 
0.08M sodium thiosulfate in distilled H2O, and 6) TBS. The 
cells were flooded with a solution of 3% hydrogen peroxide 
in distilled water for 5 min. Next, the cells were washed 
and then incubated in TBS with 1.8% normal goat serum 
(Vector, Burlingame, CA) to block nonspecific binding. The 
monolayers were finally covered with a solution of primary 
antiserum (the same rabbit antirat GH diluted 1:5000 in TBS) 
and placed in a humidified chamber for incubation at room 
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temperature. 
The final steps in the immunocytochemical staining 
sequence were carried out 2 h later by the avidin-biotin-
complex method (16), as follows: 1) wash, 2) incubation for 
30 min in biotinylated antibody (biotinylated antihuman 
immunoglobulin G diluted 1:150 in TBS; Vector), 3) wash, 4) 
incubation for 45 min in Vectastain ABC reagent (a complex 
of avidin-DH and biotinylated horseradish peroxidase 
produced just before use with reagents provided by Vector), 
5) wash, and 6) development for 5 min in a freshly prepared, 
filtered solution of 0.05% 3,3'-diaminobenz idine 
tetrahydrochloride (grade II, Sigma) and 0.01% hydrogen 
peroxide in TBS. After a series of thorough rinses, the 
slides were dehydrated and mounted in Krystalon (Harleco, 
Gibbstown, NJ). 
Use of this technique provided preparations in which 
the GH-containing cells stained a deep brown color, and 
background staining was negligible. Specificity of the 
method was confirmed by our findings that staining was 
abolished when serum from rabbits injected with adjuvant 
only (hyperimmune serum) was substituted for the primary 
antibody or when the antiserum was preabsorbed with purified 
rat GH (5ng NIADDK iodination grade/ml working dilution of 
antibody) but not highly purified PRL (in 100-fold greater 
concentrations). 
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Student's t test for paired values was used for 
statistical analysis. 
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RESULTS 
The developmental patterns of GH-containing and GH-
releasing cells are compared in Fig. 1.1. Immunocytochem-
ically detectable somatotropes were scarce (representing 
considerably fewer than 1% of all cells) in pituitary 
cultures derived from day 18 fetuses. By day 19, however, 
almost one of every four cultured cells was GH positive, and 
this proportion remained constant through day 21. GH-
secreting cells, as detected by plaque assay, were extremely 
rare on day 18, rose to appreciable numbers by day 19, and 
reached a peak by days 20 and 21. There was close agreement 
between ICC and RHPA estimates of somatotrope quantities for 
all fetal ages studied except day 19. At this time, the 
percentage of all cells that contained GH greatly exceeded 
the proportion that released the hormone under basal condi­
tions (P<0.05). Incubation with GRF did not have a 
measurable influence on the percentage of GH secretors in 
day 18 cultures, nor did it cause a significant (P>0.05) 
increase in day 19-21 cultures. 
The effects of GRF on GH release by somatotropes in 24-
h cultures of fetal pituitary cells are shown in Fig. 1.2. 
Two indices of GH secretion (the percentage of all cells in 
culture that formed plaques in a given incubation period and 
the size of plagues formed) were assessed in a short term 
(45-min antibody incubation) plaque assay. The rationale 
for using this abbreviated incubation period was as follows. 
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FIG. 1.1. Ontogeny of somatotropes during fetal develop­
ment. Different batches of cells from the same 
24h pituitary cultures were subjected to ICC and 
RHPA for GH. The plaque assays were incubated 
(with antibody) for 120 min in the presence or 
absence of GRF (1-44) (1X10~'M). The days shown 
indicate the age of the donors when pituitary 
tissue was obtained. In this and subsequent 
figures, each bar and vertical line represents 
the mean and SE of at least three separate 
experiments 
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FIG. 1.2. Responsiveness of fetal soiaatotropes to GRF. Two 
indices of 6H secretion were used to assess 
responsiveness to GRF (IxlC^M) in a short term 
(45 min antibody incubation) plaque assay. A, 
The percentage of all cells present that formed 
plagues in this abbreviated assay was used to 
estimate the rate of hormone secretion. B, The 
size of plagues that formed in the same assays 
served as an index of the relative amount of 
hormone released 
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The results of preliminary experiments (data not shown 
because a comparison of non-GRF-treated cultures in Figs. 
1.2 and 1.3 supports the same conclusion) revealed that a 
little more than half of all GH cells formed plagues in 45 
min; 120 min were required for maximal plaque development to 
occur. Thus, the 45-min incubation was chosen to optimize 
the chances of detecting a stimulatory effect of GRF on the 
percentage of plaque-forming cells. At all fetal ages 
studied, treatment with GRF significantly increased both the 
percentage of cells that formed plaques (Fig. 1.3A) and the 
size of plaques formed (Fig 1.3B). Moreover, the degree of 
stimulation (calculated as the percent increase over control 
values; transformed data not shown) was approximately the 
same at all ages studied for each variable measured. 
The inhibitory actions of somatostatin on GH release by 
individual somatotropes in culture are illustrated in Fig. 
1.3. In plaque assays of standard duration (120-min 
antibody incubation), somatostatin treatment significantly 
(P<0.05) reduced the percentage of all cultured cells that 
eventually formed plaques as well as the average size of 
those plaques on every age group studied. The degree to 
which somatostatin inhibited GH release was not influenced 
by fetal age. Short term (45-min) antibody incubations were 
not used to evaluate the inhibitory effects of somatostatin 
because the percentage of all cells in control cultures that 
formed plaques at this time was already low. 
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FIG. 1.3. Responsiveness of fetal somatotropes to 
somatostatin. A long term (120 min antibody 
incubation) plaque assay was used to evaluate the 
effects of somatostatin (IxlQ-^M) on the 
percentage of GH plaque-forming cells (A) and the 
size of the plaques that formed (B). See Fig. 
1.2 for additional details 
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DISCUSSION 
The present study was aimed at elucidating the temporal 
relationships between the initiation of hormone storage, 
basal hormone release, and the attainment of responsiveness 
to secretagogues by somatotropes during fetal development. 
The results of our immunocytochemical studies indicate that 
somatotropes first appear in appreciable numbers in pitui­
tary cultures derived from day 19 fetuses. Our findings, 
which were generated with an antiserum directed against rat 
GH, are entirely consistent with those of other investiga­
tors who used antisera for human (4, 6) or bovine (5) GH to 
identify somatotropes in sections of pituitaries from fetal 
rats. The appearance of GH-containing cells on day 19 is 
supported further by reports that this stage of development 
corresponds closely with the time at which immunoassayable 
GH appears in the pituitary (1, 3) and the plasma (2, 3) of 
the rat fetus. An added dimension of the present study was 
the quantification of the explosive appearance of fetal 
somatotropes. It was found that GH-positive cells rose from 
barely detectable levels on day 18 («1% of all cells 
present) to very high and stable levels 24 h later. More 
specifically, somatotropes accounted for 22-25% of all cells 
in pituitary cultures derived from day 19-21 fetuses. These 
values compare favorably with the 32% and 28% detected in 
24-h pituitary cultures derived from adult male and female 
rats (14, 17), respectively, and with values others have 
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obtained for pituitary sections or cultures from adults 
(18-21). Thus, somatotropes rise from negligible levels to 
proportions comparable to those in adults within an 
extremely narrow time frame (24 h or less) during fetal 
development. 
The very close agreement between plaque assay and 
immunocytochemical estimates for the size of the somatotrope 
population in pituitary cultures from day 20 and 21 fetuses, 
which is typical of that observed previously for cultures 
derived from adult male and female rats (14, 17), attests to 
the accuracy and utility of the RHPA for measuring hormone 
release from individual fetal somatotropes. However, the 
discrepancy that existed between these variables on day 19 
indicates that not all cells that contain GH actually 
release it under basal conditions. An observation similar 
to this has been reported recently for gonadotropes from 
mature female rats (22). Our finding that GRF treatment of 
day 19 cultures did not increase the percentage of plaque-
forming cells, even though some somatotropes were responsive 
to the secretagogue at this time, suggests that this 
discrepancy is probably not due to an inability to detect 
hormone secretion when it occurs. Moreoever, this differ­
ence cannot be ascribed entirely to our pooling of pitui-
taries without regard to sex, because somatotropes are 
reported to appear in pituitaries of male and female fetuses 
concurrently (4). We cannot, however, completely preclude 
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the possibility that somatotropes from fetal males and 
females may differ somewhat in responsiveness to the 
secretagogues tested. Nevertheless, it follows that the 
intracellular mechanisms responsible for the synthesis and 
storage of GH and the capacity to release the hormone under 
basal conditions probably evolve sequentially rather than 
concurrently during development. 
Previous studies designed to explore the possibility 
that the hypothalamus affects GH secretion in the fetal rat 
have yielded interesting but conflicting results. Although 
these earlier investigations did not address directly the 
responsiveness of fetal rat pituitaries to a specific 
hypothalamic GRF, there is evidence to indicate that this 
tissue might be responsive to the actions of one or more 
hypothalamic peptides with GH-releasing activity. For 
example, there is agreement that TRH, which is present in 
the fetal hypothalamus (7), is an effective stimulus for GH 
secretion from the fetal pituitary, but there are conflict­
ing reports about the developmental stage at which this 
responsiveness is attained. Rieutort (9) demonstrated that 
pituitaries from day 19 fetuses (the youngest age group 
studied) were highly responsive to TRH, whereas Khorram et 
al. (8) reported that the secretagogue was ineffective until 
day 21, the last day of gestation. Indirect evidence that 
another, better characterized GRF may modulate somatotrope 
function in the fetus was provided by Hemming et al. (23), 
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Who found that addition of synthetic GRF to cultures of 
hypophysial primordia did not accelerate the first 
appearance of somatotropes, but did increase their size and 
the intensity with which they stained immunocytochemically. 
This observation was interpreted as an indication that GRF 
increased GH biosynthesis within fetal somatotropes. 
Finally, Khorram et (8) demonstrated that crude extracts 
of hypothalami from fetal rats contained a peptidergic GRF 
which is probably different from TRH. A similar situation 
exists for the inhibitory control of GH secretion in the rat 
fetus. Hypothalamic somatostatin is detectable by RIA as 
early as days 16-17 of fetal development (8). Moreoever, 
light microscopic studies (10) reveal that neurons contain­
ing the peptide appear to terminate on the ventral surface 
of the hypothalamus by day 20 of gestation, whereas similar 
terminals have been localized electron microscopically to 
the basement membrane of the portal vessels by day 21 (11). 
Although there is a growing body of evidence to indicate 
that somatostatin is present in the fetal hypothalamus, the 
effectiveness of this peptide in inhibiting GH release from 
the fetal pituitary is as yet controversial. Rieutort (9) 
observed that somatostatin did not inhibit GH release (basal 
or stimulated by either theophylline or rat stalk median 
eminence extract) from perifused hemipituitaries of donor 
rats younger than 4 days old. Khorram et aj.. (8) obtained 
similar results with a low dose of somatostatin, but 
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observed inhibition as early as fetal day 21 with a higher 
dose. Taken together, these previous reports on GRF and 
somatostatin indicated that the hypothalamus of the fetal 
rat contained factors potentially capable of regulating GH 
release from the fetal pituitary. However, the relationship 
between the ontogenic appearance of somatotropes and the 
attainment of responsiveness to these secretagogues was 
uncertain until now. 
The results of the present study demonstrate clearly 
that somatotropes respond to hypothalamic regulatory factors 
almost from the time at which these cells first appear on 
day 19. Moreover, the relative degree of responsiveness to 
both stimulatory and inhibitory secretagogues does not 
change as a function of fetal age. Treatment of pituitary 
cells with GRF and somatostatin increased and decreased (by 
approximately the same degree at all ages studied) the 
percentage of plaque-forming cells and the size of the 
plaques that formed. We believe these two indices of GH 
secretion provide a valid means for assessing, respectively, 
the rate of hormone release and the relative amount of 
hormone secreted for the following reasons: 1) the percen­
tage of all cells that formed plaques increased progres­
sively with incubation time to a maximum which, in almost 
every instance, was identical with that measured by ICC; 2) 
plaques surrounding individual somatotropes increased in 
size as a function of incubation time; and 3) secretagogues 
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known to stimulate or inhibit GH release by entire cultures 
of pituitary cells exerted predictable effects on both 
plaque size and the percentage of cells that formed plaques. 
Thus, somatotropes from fetal rats respond to hypothalamic 
regulatory factors in a manner identical to that of their 
adult counterparts, by modulating the rate of hormone 
release as well as the amount of hormone released. It is 
difficult to reconcile our findings with those of other 
investigators (8, 9) who observed that pituitary responsive­
ness to hypothalamic secretagogues evolved, for the most 
part, postnatally. One possible explanation is that 
analysis of responsiveness at the single cell level, as 
performed in the present study, is more sensitive than that 
obtained when hemipituitaries are used. 
In summary, we have shown that the capacities of fetal 
somatotropes to store GH and release it under basal and 
regulated conditions are attained in large part within a 24 
h period between days 18 and 19 of development. This 
corresponds closely with a time at which TRH, somatostatin, 
and a non-TRH peptide with GH-releasing activity are 
detectable in the fetal hypothalamus (7, 8, 10, 11). 
Although the potential for hypothalamic control of the fetal 
pituitary is indicated by our findings and previous in vivo 
experiments (24), realization of such a relationship would 
require a route for transporting hypophysiotrophic 
substances to the adenohypophysis. These substances could 
32 
reach the anterior pituitary by diffusion or via a 
hypophysial portal system which is partially but not 
completely mature at this time (25, 26). 
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ABSTRACT 
Reverse hemolytic plaque assays and Immunocytochemistry 
were used to monitor the ontogeny of individual hormone-
secreting and hormone-containing cells in rats. Mono-
dispersed anterior pituitary cells from fetal rats (sex 
unspecified) and neonatal rats of each sex were cultured for 
24h and then subjected to immunocytochemistry or plaque 
assays for PRL or GH. PRL secretors first appeared in 
appreciable numbers in cultures from 4-day-old animals, and 
by day 5, they accounted for 8-12% of all cells in culture. 
The percentage of GH secretors rose to a peak on day 5 
(comprising "40% of all cells), when the values were 
slightly higher than those observed previously in adults. 
The percentage of cultured cells from 4- to 5-day-olds that 
released PRL or GH was not influenced by the sex of the 
donor animal and was consistent with immunocytochemical 
estimates. 
Using a sequential plaque assay that enabled the 
detection of both GH and PRL release from the same cells, we 
found that of every 100 pituitary cells from 5-day-old males 
that released PRL and/or GH, 62.5 released GH only, 1.7 
released PRL alone, and the remaining 35.8 released both 
hormones. Almost identical proportions were found for 
females. These findings were confirmed using an additional 
variation of the plaque assay and by double staining 
immunocytochemistry. Taken together, these results indicate 
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that mammosomatotropes, cells that release both 6H and PRL, 
appear early in the neonatal development of both sexes and 
raise the possibility that PRL-secreting cells arise from 
GH-secreting cells. 
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INTRODUCTION 
Recent experiments indicate that GH-containing and GH-
releasing cells first appear in pituitaries of rats during 
the latter stages of fetal development (1-8). However, 
there are conflicting reports about the ontogeny of PRL 
cells in this species. Estimates for the time at which the 
rat pituitary initiates the production and release of PRL 
range from approximately the mid-point of fetal development 
to several days after birth (4-6, 9-12). In the present 
study, we used reverse hemolytic plaque assays that enabled 
the detection of hormone release from individual cells in 
culture to determine when PRL-releasing cells first appeared 
and to monitor the postnatal development of GH secretors. 
In addition, we performed immunocytochemistry on cultures of 
pituitary cells from neonates to confirm our findings on the 
ontogeny of hormone-releasing cells. Finally, we 
investigated the possibility that some of the initial PRL 
secretors might also release GH. 
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MATERIALS AND METHODS 
Animals and cell culture 
Timed pregnant rats (Holtzman, Madison, WI) that 
arrived in our animal facility at midgestation were caged 
separately in environmentally controlled quarters (23C; 
lights on from 0600-1800h) and were allowed continuous 
access to rat chow (Simonsen, Quimby, lA) and tap water. 
The morning on which sperm were detected in the vaginal 
lavage of mated females was denoted day 0 of pregnancy, and 
the day after birth corresponded to day 1 of neonatal life. 
Anterior pituitaries from fetal rats (sex unspecified) 
and neonatal rats of both sexes were obtained aseptically 
and dispersed with trypsin essentially as described 
previously (13), except that total dispersion time was 
reduced to 30 min (tissue fragments were pipetted gently 
with a flame-polished Pasteur pipette at 15 and 30 min) for 
fetal pituitaries and to 60 min (with pipetting at 30, 45, 
and 60 min) for neonatal pituitaries. The monodispersed 
cells were plated onto 35-mm petri dishes and cultured in 
Dulbecco's Modified Eagle's Medium [DMEM; Grand Island 
Biological Co. (GIBCO), Grand Island, NY] supplemented with 
10% horse serum (GIBCO) and antibiotics (GIBCO). 
Pituitaries from male and female neonates were dispersed 
separately, and a pool of at least 12 pituitaries obtained 
from a minimum of 3 separate litters was used for each 
dispersion. 
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Plague assays 
Three versions of reverse hemolytic plague assays were 
used in this study to detect hormone release from individual 
pituitary cells in culture. All of these variations are 
based on the same principle of antibody-directed, 
complement-mediated lysis of erthrocytes proximate to 
hormone-secreting cells. Standard plaque assays (the 
simplest version) for GH or PRL were performed in the 
present study according to procedures described in detail 
previously (14-16). In short, anterior pituitary cells that 
have been cultured for 24h were recovered after a brief 
exposure (10 min) to a dilute solution of trypsin (0.025%). 
The monodispersed cells were washed twice and suspended in 
DMEM containing 0.1% BSA (fraction 5, Sigma Chemical Co., 
St. Louis, MO) and antibiotics (6IBC0). This suspension was 
diluted further with protein A-coated ovine erthrocytes 
(oRBCs) in the same medium to achieve final concentrations 
of 7.5 X 10® pituitary cells/ml and 6% oRBCs. This mixture 
was then infused by capillarity into assay chambers 
constructed previously by lowering a glass coverslip onto 
two pieces of Scotch Double-Stick Tape placed 20mm apart on 
the surface of a poly-L-lysine-coated glass microscope 
slide. During a 45 min preincubation (37C in a humidified 
atmosphere of 95% air-5% CO2), a monolayer of oRBCs and 
pituitary cells formed on the floor of the assay chamber. 
Unattached cells were then flushed out of the chambers with 
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DMEM-0.1% BSA. A solution of the same medium containing GH 
or PRL antiserum was infused into the chambers and incubated 
for 120 mln. Secretagogues such as TRH (Sigma) or human 
pancreatic 6RF (1-44) (GRF; Peninsula Laboratories, 
Belmont, CA) were colncubated with the antisera, when 
appropriate. The chambers were washed with fresh medium for 
a final time, and maximal plaque development occurred within 
60 mln of adding guinea pig serum (GIBCO) as a source of 
complement. The monolayers were fixed and stored at 4C in a 
solution of 2% glutaraldehyde-0.9% saline. The rabbit anti-
rat PRL antiserum (14) and guinea pig complement were used 
at final dilutions of 1:80 and 1:25, respectively, for all 
PRL standard plague assays. The final dilutions of monkey 
antlrat GH antiserum and guinea pig complement were 1:160 
and 1:25, respectively, for the GH assay system. 
The specificity of the standard plague assays for GH or 
PRL is supported by the results of control experiments 
conducted on pituitary cells from 5-day-old male and female 
rats. We found that 1) plaque formation was inhibited when 
antibody was omitted from the initial reaction mixture; 2) 
plaques did not form without the addition of complement; 3) 
the antisera used were highly specific, as evidenced 
previously by several criteria (14-16) and in the present 
study by our demonstration that preabsorption of working 
dilutions of each antiserum with 100 ng/ml highly purified 
homologous hormone (NIADDK lodlnation grade) completely 
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abolished plaque development, whereas 100 times greater 
amounts of heterologous hormones had no effect; and 4) there 
was close agreement between plaque assay and 
immunocytochemical estimates for the percentage of cells 
that secreted or contained each of these hormones. 
The sequential plaque assay, which has been described 
in detail previously (16), allows identification of 
individual cells that secrete both GH and PEL in addition to 
those that release only one of these hormones or the other. 
In this system, reagents for the detection of GH and PRL are 
applied to the same monolayer of pituitary cells 
consecutively. In brief, this method differs from the 
standard plaque assay in three major ways. First, only the 
pituitary cells (but not the oRBCs) are attached to the 
floor of the incubation chamber. This allows the addition 
and removal of different assay mixtures containing oRBCs, 
antibody, complement, and secretagogues without disturbing 
the pituitary cell monolayers. The initial assay mixture 
(including oRBCs as well as antibody, complement, and 
secretagogue) is flushed out with fresh medium between assay 
sequences. Second, a coverslip photoengraved with a 
numbered/lettered grid pattern (17) is used as the roof of 
the assay chamber. This aids in the reidentification of 
individual cells from sequence to sequence. Finally, 
plaque-forming cells within particular grids are recorded 
after each sequence with the aid of a vidéocassette 
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recording system attached to an inverted microscope. 
Vidéocassette recordings of each sequence are compared on 
separate monitors at the conclusion of an experiment to 
identify cells that secrete GH, PRL, or both hormones. For 
the PRL system, the antibody and complement were used at 
final dilutions of 1:40. All GH sequences were incubated in 
the presence of GRF (1 x lO^^M), and final dilutions of 
antibody and complement were 1:80 and 1:20, respectively. 
In a few experiments, a third sequence was performed. This 
was accomplished by infusing a reaction mixture identical to 
that used in the first sequence. 
Several lines of evidence support the validity of this 
system for detecting dual hormone release from neonatal 
pituitary cells. First, the specificity of each of the 
antisera was established beyond a resonable doubt (see 
standard plaque assay section of Materials and Methods). 
Second, the repeatability of plaque development from 
sequence to sequence was established by assaying for the 
same hormones in both sequences and observing that the same 
cells formed plaques in both sequences. Finally, the 
possibility of sequence to sequence carry-over of antibody 
or complement leading to nonspecific plaque development was 
controlled by deletion, substitution, and preabsorption (of 
antibody) experiments in both sequences. The possibility 
that such interactions occurred was reduced further by our 
finding that the proportions of the three cell types 
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Identified remained constant regardless of whether GH or PRL 
was detected in the first sequence. 
A fixed sequential assay (16) was employed to estimate 
the total percentage of all cultured pituitary cells that 
released GH and/or PRL. The term fixed derives from the 
fact that both pituitary cells and oRBCs are affixed to the 
floor of the assay chamber, while sequential relates to the 
step-wise addition of reagents for detecting the release of 
GH and PRL. This assay was conducted in a manner identical 
to that of the standard plaque assay, except that 1) 
photoengraved coverslips were used to construct the assay 
chambers, and 2) the same monolayers of pituitary cells and 
oRBCs were incubated sequentially with reagents for 
detecting GH and PRL release. The latter was accomplished 
by infusing a single solution containg antiserum, 
complement, and secretagogue (when appropriate) at the 
beginning of each sequence. Vidéocassette recordings of 
plaque formers were obtained at the end of each sequence. 
The assay mixture for the GH sequence contained GH antiserum 
and complement at dilutions of 1:80 and 1:20, respectively, 
and GRF (1 X 10~^M). The PRL antiserum was used at a final 
dilution of 1:60, with complement at 1:20. In addition to 
developing for GH in the first sequence followed by PRL in 
the second and vice versa, we developed for the same hormone 
in both sequences. The number of plaque-forming cells was 
the same when a given antibody was used in one or both 
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sequences, indicating that incubation in the first sequence 
was sufficient for detection of all hormone-releasing cells 
of a given type. 
Immunocvtochemistrv 
Localization of GH or PRL in pituitary cells derived 
from fetal (days 18-21) and neonatal (5-day-old) rats of 
both sexes was accomplished immunocytochemically with the 
avidin-biotin-peroxidase complex (ABC) method (16, 18). 
Specifically, 24h cultures of pituitary cells were 
retrypsinized (as described above), seeded onto poly-L-
lysine-coated glass microscope slides, and incubated at 37C 
for 45 min. The slides were then placed in trays at room 
temperature and washed gently three times with Tris-buffered 
saline (TBS; 0.05M Tris and 0.15M NaCl in distilled H2O, pH 
7.6) for 5 min each time. This same procedure was repeated 
for all subsequent washes. Freshly prepared fixative (0.25M 
mercuric chloride, O.IM sodium acetate, and 4% final 
concentration of formaldehyde in distilled H2O) was applied 
to the monolayers for 10 min and then replaced with the 
following for 1 min each: 1) 95% ethanol in distilled H2O, 
2) distilled H2O, 3) Lugol's iodide (0.08M iodine and 0.12M 
potassium iodide in distilled H2O), 4) distilled H2O, and 5) 
0.08M sodium thiosulfate in distilled H2O. This was 
followed by the sequential addition of TBS (10 min) and 3% 
hydrogen peroxide in distilled H2O (5 min), after which the 
monolayers were washed with TBS and covered with a solution 
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Of normal goat serum in TBS for 20 min. After application 
of primary antiserum^ the monolayers were incubated at room 
temperature for 2h in a humidified atmosphere. The same 
monkey antirat GH antiserum used for plague assays was 
diluted 1:15,000 in TBS for immunocytochemistry, whereas a 
different PRL antiserum (JDN 10) (14) was diluted 1:10,000 
in TBS for this purpose. The cells were then washed and 
incubated with a solution of biotinylated second antibody 
for 30 min. PRL antibody was followed by treatment with 
biotinylated antirabbit immunoglobulin G, and biotinylated 
antihuman immunoglobulin G was employed to localize the GH 
antibody. All ABC reagents were purchased from Vector 
Laboratories (Burlingame, CA) and used according to the 
directions provided. The cells were subsequently washed, 
covered with the Vectastain ABC reagent (45 min), and washed 
again. Finally, the slides were submerged for 5 min in a 
freshly prepared filtered solution of 0.05% 3,3'-
diaminobenzidine tetrahydrochloride (Sigma) and hydrogen 
peroxide (0.025%) in distilled H2O. After development, the 
monolayers were washed thoroughly in tap water, dehydrated, 
and then mounted with Krystalon (Harleco, Gibbstown, NJ). 
The suitability of these antisera for immunocytochemistry 
was demonstrated by control experiments in which we found 
that preabsorption of working dilutions of each antiserum 
with highly purified homologous hormone (the same ones 
described earlier at 100 ng/ml, the lowest dose tested) 
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abolished staining, whereas 100 times greater amounts of 
heterologous hormone did not have an effect. Additional 
experiments, in which we substituted normal rabbit serum for 
antibody or deleted various other components one at a time, 
served as procedural controls. 
Double staining immunocytochemistry (16) was used to 
estimate the cumulative percentage of all pituitary cells 
that contained GH and/or PRL. This involved performing the 
immunocytochemical staining sequence for one of these 
hormones on a pituitary cell monolayer that had already been 
stained for the other hormone. The procedures used were 
virtually identical to those described above, except that 1) 
the pituitary cells were attached to the surface of 
photoengraved microscope slides, so that the same cells 
could be identified during the two staining sequences; and 
2) the second staining sequence was initiated with the 
hydrogen peroxide step to ensure complete inactivation of 
peroxidase (ABC reagent) added at the end of the first 
sequence. Steps to remove immunoreactants between sequences 
were not taken because they were not indicated by procedural 
controls (see below). The chromogen for the second staining 
sequence was the same one used earlier (3,3'-
diaminobenzidine tetrahydrochloride). Vidéocassette 
recordings of cells were made at the end of each staining 
sequence and compared at a later time. As procedural 
controls for every experiment, we incubated monolayers with 
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the following combinations of reagents at the primary 
antibody (AB) step of the first and second sequences, 
respectively: 1) GH-AB:GH-AB; 2) PRL-AB:PRL-AB; 3) GH-AB or 
PRL-AB;no second sequence; 4) GH-AB or PRL-AB;TBS; 5) 
TBS:PRL-AB or GH-AB. Using this approach, we consistently 
found that a single sequence was sufficient for detection of 
all hormone-containing cells of a given type, and there was 
no interaction between the reagents used in the two 
sequences. 
Student's t test (19) was used for statistical 
analysis. 
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RESULTS 
The ontogenlc patterns of PRL-releasing cells in male 
and female rats are Illustrated in Figs. 2.1 and 2.2. PRL 
secretors, as detected by standard plague assay, were 
extremely rare (accounting for considerably less than 1.0% 
of all cells) in pituitary cultures derived from fetal and 
3-day-old rats. Cells that released PRL first appeared in 
appreciable numbers on day 4 and represented 8-12% of all 
cells in pituitary cultures from 5-day-old animals. The 
explosive appearance of these cells between days 3 and 4 was 
similar for both sexes and was not influenced significantly 
(P < 0.05) by the presence of TRH. The percentage of PRL-
releasing cells continued to rise through day 10 for both 
sexes, but the increase was most striking for females. In 
each instance, however, the day 10 values were still 
considerably lower than those measured previously in adults 
(14, 20). 
The neonatal patterns of development for GH-releasing 
cells were virtually identical for males and females (Figs. 
2.3 and 2.4). The percentages of GH secretors in control 
experiments were already over 25% on day 3 (the youngest age 
group studied), rose to a peak on day 5, and declined 
slightly by day 10. Treatment with GRF did not 
significantly affect the percentages of GH-releasing cells 
at any of the ages tested except on day 10, when it caused a 
slight but significant (P < 0.05) increase in both sexes. 
53 
'Ji 
"3 
U 
03 
V 
U 
V 
C/5 
U 
_2 
0 
u 
0. 
33 -
31h  
15^ 
I 
13-
1 1 -
9r 
I 
7l-
5-
3-
irrrrr 
-4 -2 
1 
o—o TRH 
# # Control 
0 2 3 4 5 
Age (Days) 
10 Adult 
FIG. 2.1. Ontogeny of PRL-releasing cells in male rats. 
Anterior pituitaries from fetal (-4 to -1 denote 
fetal days 18-21) and neonatal male rats were 
dispersed with trypsin, cultured for 24h, and 
then subjected to reverse hemolytic plague assays 
for PRL. The day of birth is designated day 0. 
Shown for each age is the percentage (mean ± SE; 
n=3 separate experiments) of all cells in culture 
that formed plaques in the presence or absence 
of TRH (IxlO'^M). For comparison, we have 
included values for adult male rats from a 
previous study (20) 
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FIG. 2.2. Ontogenlc pattern of PRL-releaslng cells In 
female rats. See Fig. 2.1 for additional 
details. For comparison, adult female values 
from a previous study (14) have been Included 
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FIG. 2.3. Neonatal development of GH-releasing cells in 
male rats. Twenty-four-hour pituitary cultures 
from male rats (days 3, 4, 5, and 10 after birth) 
were subjected to reverse hemolytic plaque assays 
for GH. The percentage (mean + SE; n=3 separate 
experiments) of all cultured cells that formed 
plagues in the presence or absence of GRF (Ix 
10"%) is shown. Values for adult males from a 
previous study (20) have been included for 
comparison 
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FIG. 2.4. Neonatal development of GH-releasing cells in 
female rats. See Fig. 2.3 for additional 
details. Also included for comparison are adult 
female values from a previous investigation (14) 
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Immunocytochemlstry for GH and PRL was performed on 24h 
pituitary cultures derived from 5-day-old male and female 
rats in an attempt to validate further the use of GH and PRL 
standard plaque assays on neonatal pituitary cells. As can 
be seen by comparing the values presented in Table 2.1 with 
the data illustrated in Figs. 2.1-2.4, there was very close 
agreement between plaque assay and immunocytochemical 
estimates of the size of the GH- and PRL-releasing and -
containing cell populations. Immunocytochemistry for PRL 
was also conducted on 24h pituitary cultures from day 18-21 
fetuses (n=3 experiments for each age group). None of the 
fetal cultures studied contained PRL-positive cells (data 
not shown). 
The sequential version of the plaque assay was used to 
quantify the proportions of GH- and/or PRL-secreting cells 
in cultures derived from 5-day-old rats of each sex. 
Examples of plaque-forming cells in representative assays 
are shown in Figs. 2.5 and 2.6, and the results obtained 
with this method are summarized in Fig. 2.7. We found that 
of every 100 of these hormone-secreting cells identified in 
pituitary cultures from males, a proportion of 62.5 released 
GH only, 1.7 released PRL alone, and the remaining 35.8 
released both of these hormones. Almost identical 
proportions (62.2, 2.2, and 35.6, respectively) were found 
for females. Thus, the vast majority of PRL secretors from 
5-day-old rats also released GH. 
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TABLE 2.1. Immunocytochemical estimates of 6H- or PRL-
containing cell populations in 24h cultures of 
anterior pituitaries from 5-day-old male and 
female rats& 
Hormone 
detected Male (%) Female (%) 
GH 40.97 ± 0.35 41.47 + 0.25 
PRL 11.60 ± 0.74 9.67 ± 0.03 
^Shown are the percentages (mean + SE; n=3 separate ex­
periments) of all cells in culture that stained immunocyto-
chemically for GH or PRL. 
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FIG. 2.5. Photomicrographs of plaque-forming cells in a 
sequential plaque assay. Pituitary cells from 
neonatal male rats were incubated with reagents 
for detecting GH in the first sequence (left 
panel) and PRL in the second sequence fright 
panel) Coverslips photoengraved with a 
numbered/lettered grid pattern were used to 
facilitate reidentification of the same cells in 
each sequence. Plaques are the clear areas 
(formed by antibody-directed complement-mediated 
lysis of oHBCs) with a pituitary cell in the 
center. The smaller cells are oRBCs, while the 
larger ones are pituitary cells. Mammosomato-
tropes, cells that release both GH and PRL, 
induced plaque development in each sequence. 
Cells that released GH alone formed plaques in 
the first sequence only 
FIG. 2.6. Photomicrograph of a sequential plaque assay in 
which cells that released only PRL were detected. 
In this particular experiment, a pituitary 
monolayer was developed with reagents for 
detecting the release of PRL first, GH second, 
and PRL third. Upper panel. A single plaque-
forming cell is present. Middle panel. Several 
GH plaque-forming cells are shown. Note that the 
single cell that formed a plaque in the presence 
of PRL antiserum (upper panel) did not develop 
when incubated with GH antiserum (middle panel). 
Lower panel. The same PRL-releasing cell detected 
in the first sequence (upper panel) formed a 
plaque in the third sequence. Also note that 
none of the GH-releasing cells observed in the 
second sequence were detected here. This type of 
experiment shows that plaque formation is 
repeatable in subsequent sequences (compare the 
top and bottom panels) even when an intervening 
incubation (middle panel) is directed toward a 
different hormone. Moreover, these results 
demonstrate that there is no interaction among 
reagents used in different sequences 
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FIG. 2.7. Distribution of PRL- and/or GH-releasing cells in 
24h cultures of pituitaries from 5-day-old male 
and female rats. A sequential plaque assay that 
enabled the detection of both GH and PRL release 
from the same cells was used to determine the 
proportions of plaque-forming cells that released 
one or both of these hormones. The proportional 
values are expressed as the number of cells per 
100 GH and/or PRL plaque-forming cells (mean ± 
SE; n=3 separate experiments) 
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The results of experiments with the fixed sequential 
assay are shown in Table 2.2. When pituitary monolayers 
from 5-day-old rats (equal numbers of male and female 
pituitaries were pooled for each dispersion) were incubated 
with reagents for detecting 6H release first and PRL second, 
only a few additional plaque-forming cells were detected 
after the second sequence. The small fraction of all GH 
and/or PRL cells identified in this manner as secreting PRL 
but not GH closely approximated that detected with the 
sequential assay. The observation that the same number of 
cells formed plaques when the same antiserum was used in 
both sequences demonstrated that plaques develop maximally 
in a single sequence. The increase in plaques observed when 
reagents for detecting PRL release were followed by those 
for GH indicates that formation of plaques in the first 
sequence did not interfere with plaque development in the 
second. 
GH-containing and PRL-containing cells in pituitary 
cultures from 5-day-old rats were detected immunocytochem-
ically, and the degree of overlap between these cell 
populations was estimated indirectly by use of double 
staining immunocytochemistry. As shown in Table 2.3, few 
additional cells stained in a second sequence for PRL after 
a sequence in which GH-positive cells were detected. That 
reagents used in the first sequence did not inhibit staining 
in the second is supported by results of experiments in 
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TABLE 2.2. Detection of GH- and/or PRL-releasing cells by 
use of a fixed sequential plaque assay^ 
First sequence Second sequence 
Hormone release No. of Hormone release No. of 
detected PFCs detected PFCs 
GH 660 
GH 450 
PRL 167 
PRL 111 
PRL 669 
GH 450 
PRL 167 
GH 365 
^Monodispersed pituitary cells from 5-day-old rats were 
cultured for 24h before use. Pituitaries from males and 
females were combined in equal proportions for each experi­
ment. The number of plaque-forming cells shown represent 
the cumulative results of three separate experiments. PFCs, 
Plaque-forming cells. 
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TABLE 2.3. Double staining immunocytochemical detection of 
GH- and/or PRL-containing cells in 24h pituitary 
cultures from 5-day-old rats& 
First sequence Second sequence 
Hormone Hormone 
detected % Stained detected % Stained 
GH 37.94 ± 0.33 PRL 40.37 ± 0.43 
PRL 9.72 + 0.46 GH 41.23 + 1.06 
GH 38.81 + 0.53 GH 39.39 ± 0.46 
PRL 9.80 + 0.04 PRL 10.00 + 0.05 
^Values are the mean ± SE (n=3 separate experiments). 
Pituitaries from males and females were combined in equal 
proportions for each experiment. A total of 2095 cells 
stained positively for GH in the first sequence whereas only 
53 additional cells (2148 in all) stained in the second se­
quence . 
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which PRL-containing cells were detected in the first 
sequence (9.72%) and GH-positive cells were identified in 
the second (41.23%). In addition, our finding that similar 
percentages of all cells stained at the end of both 
sequences, when the same antibody was used consecutively, 
indicates that detection of hormone-containing cells was 
maximal after a single sequence. As was the case for the 
fixed sequential assay, double staining immunocytochemical 
estimates for the size of the population of cells that 
contained only PRL were in very close agreement with the 
direct measurements obtained with the sequential plaque 
assay. 
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DISCUSSION 
The objective of this study was to monitor the 
development of GH- and PRL-secreting cells in rats. Our 
current understanding of this area is based on 
radioimmunological measurements of hormone concentrations in 
pituitary extracts and plasma samples (1-3, 7, 10-12) and on 
immunocytochemical detection of hormone-containing cells in 
sections of pituitaries (4-6, 8, 9) from fetal and neonatal 
rats. A major limitation of this first approach has been 
that only the average contribution of all cells involved 
with the production or release of a particular hormone could 
be assessed; it provided little insight into the ontogeny of 
entire populations of endocrine cells. Likewise, 
information obtained with the immunocytochemical approach 
has been inconclusive, because many cells that contain a 
particular hormone might not secrete it at any given time 
(21). Therefore, in the present study we employed both 
reverse hemolytic plaque assays to monitor the ontogeny of 
GH- and/or PRL-releasing cells in pituitary cultures derived 
from neonatal rats and immunocytochemistry to assess the 
size of the cell populations that contained these hormones. 
Radioimmunological and immunocytochemical evidence 
related to the ontogenic pattern of PRL cells in rats is 
both extensive and conflicting. For example, Gash et al. 
(11) reported that immunoreactive PRL concentrations were 
detectable but extremely low in pituitary anlagen of day 12 
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and 15 rat fetuses and that these values were not any higher 
in neonates. Khorram et (12), on the other hand, first 
detected immunoreactive PRL in pituitaries obtained from day 
18 fetuses and found that the most striking increase in 
pituitary content of this hormone occurred between fetal day 
20 and the second day of neonatal life. In contrast, Oliver 
et al. (10) found that PRL was not measurable (2.5 ng) in 
pituitaries of day 17-20 fetuses, the pituitary content of 
the hormone rose to barely detectable levels at term, and 
these values then increased more than 50-fold in both sexes 
to an initial peak on day 7, which was followed by a decline 
until day 13. Immunocytochemical data on the appearance of 
PHL-containing cells in pituitaries of developing rats are 
also controversial. Watanabe and Daikoku (6) reported that 
PRL-positive cells were not present in pituitaries of fetal 
rats at any gestational age and were very rare in newborns 
(0-1 day old). Similar results were obtained by Chatelain 
et al. (4, 9), who detected PRL-containing cells in 
pituitaries of day 21 fetuses, but observed that the 
intensity of staining was very weak until the fourth 
postnatal day. In contrast, Setalo and Nakane (5) 
consistently observed PRL-positive cells in pituitaries of 
day 17 fetuses. Thus, on the basis of previous evidence, 
PRL cells evolve sometime between the midpoint of fetal 
development and the early neonatal period. The results of 
the present study indicate that the ontogenic appearance of 
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PRL-releasing and PRL-containing cells occurs, in large 
part, after birth. This conclusion is supported by our 
finding that PRL-releasing (plague assay) and PRL-containing 
(immunocytochemistry) cells were extremely rare in pituitary 
cultures derived from day 18-21 fetuses. The number of 
cells that secreted PRL rose from virtually undetectable 
levels on day three after birth to approximately 9% of all 
cells in culture by day 4. Moreover, this explosive 
appearance of PRL-releasing cells between days 3 and 4 was 
not influenced by the gender of the donor animal. That our 
estimates of the size of the PRL cell population were 
accurate is supported by the following observations. 1) 
Acute treatment with TRH, which is reported to stimulate PRL 
release from entire pituitaries of neonatal rats (12), 
affected neither the day on which PRL-releasing cells first 
appeared in large numbers nor the percentage of all cultured 
cells committed to PRL release after day 3. 2) When PRL 
plaque assays and immunocytochemistry were performed on 
different batches of cultured pituitary cells from 5-day-
old rats, there was very close agreement between the 
relative percentages of PRL-releasing and PRL-containing 
cells. 3) PRL cells were not detected (<0.5%) when plaque 
assays and immunocytochemistry for this hormone were run on 
freshly dispersed pituitaries from 2-day-old rats, 
indicating that the inability to measure PRL before day 4 
was not due to an artifact of culture. Taken together, our 
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results demonstrate that PRL cells from the rat pituitary 
appear, for the most part, during a very narrow time frame 
between days 3 and 4 of neonatal life. 
It is generally accepted that GH cells first appear in 
the rat pituitary on the 19th day of fetal development. 
This conclusion is supported by radioimmunological 
measurements of GH in pituitaries and plasma of fetal rats 
(1-3, 7), by immunocytochemical detection of GH-containing 
cells in sections of pituitaries from fetal rats (4-6), and 
most recently, by our application of a reverse hemolytic 
plaque assay and immunocytochemistry for GH to cultures of 
pituitary cells from fetal animals (8). In the present 
investigation, we extended these earlier studies by 
quantitatively monitoring the postnatal development of GH 
cells for comparison with that of PRL cells. The percentage 
of GH-releasing cells in both males and females increased 
progressively during the early neonatal period to a peak on 
day 5 and then declined slightly by day 10. Acute treatment 
with GRF did not have a striking influence on the percentage 
of all cultured cells committed to GH release. This 
observation coupled with the close agreement between plaque 
assay and immunocytochemical estimates for GH cells on day 5 
indicate that most, if not all, GH secretors had been 
detected in control cultures. It is noteworthy that the 
relative number of GH-releasing cells was greater in 
pituitary cultures derived from 5-day-old males and females 
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than from those of adults (15, 20). Moreover, the highest 
concentration of GH-releasing cells was observed at 
approximately the same time that PRL cells first appeared. 
A comparison of our previous (8) and present data suggest 
that the ontogenic appearance of GH cells precedes that of 
PRL cells by approximately 1 week. Such a relationship is 
not consistent with reports by Khorram et (7, 12) that 
both GH and PRL are first detectable by RIA on day 18 of 
fetal development, or with the observation by Setalo and 
Nakane (5) that immunocytochemically positive PRL cells 
appear 2-3 days before GH cells in the pituitary of the 
fetal rat. However, our view is consonant with the 
immunocytochemical observations of Watanabe and Daikoku (6) 
and Chatelain et (4, 9), who investigated the ontogeny 
of both cell types in rats and found that GH-containing 
cells preceded PRL-containing cells by a substantial 
interval. Furthermore, this order of appearance is 
characteristic of that for other species, such as humans 
(22, 23), sheep (24, 25), pigs (26, 27), cattle (28), and 
mice (29). 
The temporal relationship between the ontogeny of GH-
and PRL-secreting cells raises an interesting question. Do 
PRL cells arise from GH cells? The bulk of evidence 
available for other species would not favor an affirmative 
answer to this question. For example, GH and PRL are 
contained in separate and distinct cells within pituitaries 
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Of fetal humans (22, 30), sheep (24), cattle (28, 31), and 
pigs (26, 32). However, the situation for fetal rats is not 
so clearly defined. Chatelain and co-workers (4) 
immunocytochemically stained contiguous sections of 
pituitaries from day 21 rat fetuses with antisera to GH or 
PRL and found that although most GH cells differed 
from PRL cells, there were some cells that contained both 
hormones. The possibility of an ontogenic interconversion 
of GH and PRL cells in fetal rats is supported by the 
observation of Strattmann et (33) that somatotrophs 
(labeled with [^H]thymidine) acquired the ultrastructural 
characteristics of mammotrophs after treatment of male rats 
with estrogen. Recent reports on the presence of mammoso-
matotropes, cells that release both GH and PRL in disper­
sions of pituitary cells from mature male and female rats 
(16, 34), are also consistent with this concept. Therefore, 
the existence of similar dual, possibly transitional, cells 
in the neonatal pituitary would be a reasonable expectation 
if, indeed, PRL cells arose from GH cells during develop­
ment. 
Our data demonstrate clearly that the first PRL-
secreting cells detected in cultures of neonatal rat 
pituitaries also released GH. This conclusion is supported 
by considerable evidence obtained by use of the sequential 
plaque assay, the fixed sequential plaque assay, and double 
staining immunocytochemistry. The results of our 
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experiments with the sequential plaque assay provide direct 
evidence for the presence of mammosomatotropes in pituitary 
cultures from neonates. When separate plaque assays for GH 
and PRL were performed sequentially on the same pituitary 
cell monolayers from 5-day-old rats, almost all of the cells 
that released PRL in one sequence were found to release GH 
in the other. In contrast, a minority of GH cells were 
observed to release PRL also. Indirect evidence to confirm 
the existence of mammosomatotropes in neonatal pituitaries 
was obtained by use of the fixed sequential assay. This 
assay is conceptually identical with the standard plaque 
assay, in that both pituitary cells and oRBCs are attached 
(fixed) to the floor of the incubation chamber. The major 
difference is that reagents for detecting GH and PRL are 
applied to the same monolayers sequentially. The primary 
advantage of this system over the sequential assay is that a 
given cell is identified as a plaque former only once; 
therefore, possible artifacts of the sequential assay 
arising from sequence to sequence interactions not detected 
by our extensive control procedures can be completely 
avoided. When fixed pituitary and oRBC monolayers were 
incubated first with reagents for detecting GH release and 
later with reagents for PRL, only a few additional plaque-
forming cells were detected after the second sequence that 
were not present after the first. These findings are 
consonant with the view that most PRL secretors from 
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neonatal rat pitultaries also release GH. The final piece 
of evidence in this regard was derived from experiments in 
which double staining immunocytochemistry was performed on 
pituitary cells from 5-day-old rats. The rationale for this 
approach and the results obtained were very similar to those 
for the fixed sequential assay. The percentage of cells 
that stained immunocytochemically when both GH and PRL 
antisera were applied sequentially to the same pituitary 
monolayer was only slightly higher than that obtained when 
GH antiserum was used alone and was considerably less than 
the cumulative percentage obtained when each antisera was 
used separately. Thus, our findings on hormone storage 
within pituitary cells, when taken together with our plaque 
assay data, provide compelling evidence that most PRL cells 
from the neonatal rat pituitary are also GH cells. 
Moreover, these three techniques used to identify 
maimosomatotropes provided very similar estimates for the 
fraction of all GH and/or PRL cells that contained or 
released PRL alone (estimates from the three techniques 
ranged from 1.3-2.5 of every 100 GH and/or PRL cells). 
In summary, we have used three variations of reverse 
hemolytic plaque assays and two modifications of 
immunocytochemistry to investigate the development of GH and 
PRL cells in pituitaries of neonatal rats. Our results show 
that PRL cells first appear abruptly during a very narrow 
time frame between days 3 and 4 of postnatal life. This is 
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a time at which the GH cell population is already firmly 
established. In addition, our data demonstrate that most of 
these initial PRL cells are also GH cells. These findings 
raise the possibility that GH cells give rise to PRL cells 
during development. Of course, acceptance of this view will 
require the demonstration that specific cells committed 
exclusively to GH release on day 3 can be induced to secrete 
PRL on day 4. Studies aimed at addressing this possibility 
are currently underway. 
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ABSTRACT 
Hypothalmic factors have been shown to regulate acutely 
the synthesis and release of adenohypophyseal hormones, yet 
few studies have investigated the long-term effects of these 
agents on adenohypophyseal cell types. In the present 
study, we assessed the chronic influence of selected 
hypothalamic factors on the relative proportions of GH- and 
PRL-secreting cells in pituitary cultures derived from 5-
day-old rats. Primary cultures were established and 
incubated for 6 days in the presence or absence of 0.1 uM 
doses of GRF, LHRH, CRF, TRH, or VIP and then subjected to 
reverse hemolytic plaque assays for analysis of the 
percentages of cells that released GH or PRL. In cultures 
from males, GRF and LHRH treatment caused an increase in the 
proportion of PRL secretors and a commensurate decrease in 
the GH population. CRF increased PRL cells without 
affecting the GH-secretors, while TRH reduced the percentage 
of both cell types, and VIP had no effect. Virtually 
identical results were obtained for cells isolated from 
females. These results demonstrate that hypothalamic 
factors have the capacity to induce differential effects on 
the proportions of GH- and PRL-secreting cells. 
Surprisingly, our findings also show that hypothalamic 
factors that do not normally influence the acute release of 
GH or PRL can exert a chronic effect on the proportion of 
cells that secrete these hormones. 
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INTRODUCTION 
It is well established that the synthesis and release 
of adenohypophyseal hormones are under stimulatory and/or 
inhibitory control by hypothalamic hypophysiotropic factors 
(1-10). These substances are produced in hypothalamic 
neurons, enter the hypothalamo-hypophyseal portal veins at 
the median eminence, and exert their effects on the cells of 
the adenohypophysis, as originally suggested by Harris (11). 
Although the acute effects of these factors on adenohypophy­
seal function have been characterized extensively, few 
studies have dealt with the chronic influence of these 
agents on the cells of the anterior pituitary gland. Most 
of the evidence favoring a chronic influence of the 
hypothalamus on anterior pituitary function comes from in 
vivo studies of experimental and natural anencephaly (12-14) 
or hypophyseal stalk-transection (15-16). The results of 
these investigations strongly suggest that hypophysiotropic 
input is required not only for normal differentiation, but 
also for the maintenance of hormone-secreting cell types of 
the adenohypophysis. 
In the present study, we used reverse hemolytic plaque 
assays to elucidate the chronic influence of selected 
hypothalamic factors on GH- or PRL-secreting cells in 
anterior pituitary cell cultures. 
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MATERIALS AND METHODS 
Animals and cell culture 
The 5-day-old male and female rats used in this study 
were reared from Holtzman (Madison, WI) stock within our 
environmentally-controlled (23C; lights on from 0600-1800h) 
animal facility. The mothers were allowed continuous access 
to rat chow (Simonsen, Quimby, lA) and water. The day after 
birth was denoted day 1 of neonatal life. 
Anterior pituitary glands were removed aseptically 
following decapitation and dispersed with trypsin as 
described previously (17) with a total dispersion time of 60 
min. Pituitary glands from males and females were dispersed 
and assayed separately, yet simultaneously to minimize any 
differences in dispersion conditions or reagents. A pool of 
at least 12 pituitary glands obtained from a minimum of 3 
separate litters was used for each dispersion and five 
different dispersions were treated and analyzed for each 
sex. The monodispersed cells were then plated onto 35mm 
petri dishes at 1 x 10® cells/dish and cultured for 6 days 
in Dulbecco's Modified Eagles Medium (DMEM), supplemented 
with 10% horse serum and antibiotics (100 ug/ml streptomycin 
sulfate, 100 U/ml penicillin G). Experimental cultures were 
treated immediately with either vehicle or 0.1 uM secreta-
gogue [either human pancreatic growth hormone-releasing 
factor 1-44 (GRF), luteinizing hormone-releasing hormone 
(LHRH), ovine corticotropin-releasing factor (CRF), 
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thyrotropin-releasing hormone (TRH), or vasoactive intesti­
nal polypeptide (VIP)]. The media was changed once (day 3) 
during each 6-day culture period. 
Plague assays 
Standard plaque assays for GH and PRL were conducted 
essentially as described previously (18), except that a 
single 4h antibody incubation was utilized. In short, the 
6-day cultured cells were removed from the 35mm petri dishes 
after a mild retrypsinization, and the percentage of cells 
recovered per treatment was calculated with the aid of a 
hemocytometer. The cells were then mixed with protein-A 
coated ovine red blood cells (oRBCs) and infused into assay 
chambers. Following attachment, the monolayers were washed 
with fresh DMEM containing 0.1% BSA and antibiotics. After 
washing, a 1:160 dilution of monkey-anti-rat GH serum (19), 
or a 1:160 dilution of rabbit-anti-rat PRL serum (20), in 
the above medium, was infused into the chambers. Four hours 
later, a 1:40 dilution of guinea pig complement was added 
and maximal plague development occurred within the next 50 
min. The slides were then fixed with 1.8% glutaraldehyde in 
isotonic saline, stained with toluidine blue-0 and analyzed 
microscopically. At least 300 cells were counted on each 
slide and a minimum of 2 slides were analyzed for each 
treatment (data point) from a single experiment. Each 
experiment was repeated at least 5 times using cultures 
derived from separate dispersions. 
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The specificity of our 6H and PRL antisera have been 
demonstrated previously (19-21). As procedural controls, 
omission of hormone-specific antisera or guinea pig 
complement in either assay completely abolished plague 
formation. 
Reagents 
All tissue culture media, antibiotics, guinea pig 
complement and horse serum were obtained from Grand Island 
Biological Co., Grand Island, NY. Human pancreatic growth 
hormone-releasing hormone 1-44 was purchased from Peninsula 
Laboratories, Belmont, CA, whereas all other secretagogues 
(LHRH, CRF, TRH, and VIP) were obtained from Sigma Chemical 
Co., St. Louis, MO. Bovine serum albumin (Fraction 5) was 
also purchased from Sigma. 
Statistical analysis 
The statistical significance of differences between 
experimental groups and controls was analyzed by one-way 
analysis of variance followed by Tukey's multiple range test 
( 2 2 ) .  
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RESULTS 
The average number of cells recovered from 6-day 
control cultures or those treated with hypothalamic factors 
ranged from 64 to 85%, however, there was no statistically 
significant difference in cell recovery between any of these 
cultures. Therefore, although we cannot address indiscrim­
inate or selective cell death directly, we feel that the 
effects of such processes were minimal and could not account 
in large part, for the effects caused by the secretagogues 
tested. 
The influence of selected hypothalamic regulatory 
factors on the relative number of GH- and PRL-secreting 
cells in pituitary cultures derived from 5-day-old male rats 
is shown in Fig. 3.1. All but one of the factors tested 
affected the percentages of hormone secretors in these 
cultures. Chronic treatment of cultures with GRF, LHRH, or 
CRF significantly (p<0.01) increased the percentage of PRL 
releasors from a control value of 15.7 ± 0.2% (X ± SE, n = 5 
separate experiments) to 23.9 + 1.0%, 21.6 ± 0.9% and 21.5 ± 
0.3%, respectively. TRH had the opposite effect (to 11.2 ± 
0.1%) and VIP was ineffective. When plaque assays for GH 
were performed on different batches of cells from the same 
cultures, we found that chronic treatment with GRF, LHRH, or 
TRH significantly (E<0.01) reduced the percentage of GH-
secretors from 35.0 + 0.6% in controls to 26.4 + 0.8%, 29.0 
+ 0.9% and 25.4 + 0.4% respectively, whereas, CRF and VIP 
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FIG. 3.1. Effects of hypothalamic regulatory factors on GH 
and PRL cell populations in males. Dispersed 
anterior pituitary cells from 5-day-old male rats 
were cultured as monolayers in the presence or 
absence of 0.1 M doses of GRF, LHRH, TRH, CRF, 
or VIP. After 6 days of treatment, we recovered 
the cells following a brief retrypsinization and 
then performed plague assays for GH and PRL. 
Shown here are the results of 5 separate 
experiments (mean ± SE) in which a minimum of 300 
cells were analyzed on 2 separate plaque assay 
slides in each experiment. The horizontal lines 
denote control values. For example, in controls, 
approximately 16% of all cells in culture were 
PRL secretors and 35% were GH secretors. In this 
and the subsequent figure, the stars designate 
values that are significantly (E<0.01) different 
from controls 
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had no significant effects. Virtually identical results 
were obtained with cultures from 5-day-old female rats (Fig. 
3.2), except that the increase in the percentage of PRL-
secretors in cultures treated with CRF was not significantly 
different from controls (e>0.05). 
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FIG. 3.2. Effects of hypothalamic regulatory factors on GH 
and PRL cell populations in females. See the 
legend to Fig. 3.1 for additional details. Note 
that the patterns of GH and prolactin cell 
populations after treatment are similar to those 
of males (Fig. 3.1) 
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DISCUSSION 
In recent years numerous studies have documented the 
acute effects of hypothalamic factors on adenohypophyseal 
function. More specifically, these factors are reported to 
either stimulate or inhibit both the synthesis and release 
of anterior pituitary hormones (1-10). However, a more 
classical view of the hypothalamo-hypophyseal interaction is 
evident from earlier studies which showed the hypothalamus 
to be essential for the development and maintenance of 
pituitary cell types. A role for the hypothalamus in the 
differentiation of the adenohypophysis is suggested by 
studies of natural and experimental anencephaly (12-14) and 
by investigations with anterior pituitary anlagen cultured 
in vitro (23-29). The results of these studies indicate 
that the adenohypophysis will differentiate to a limited 
degree in the absence of hypothalamic influence but that 
hypophysiotropic input is generally required for completion 
of this process. Experiments with mature animals support 
similar conclusions. Hypophyseal stalk-transection is 
followed within a few weeks by a loss of identifiable 
hormone containing cells within the pituitary (15, 16). 
Likewise, transplantation of the pituitary gland to sites 
devoid of direct hypothalamic influence has also been shown 
to alter pituitary function (25, 29, 30-33), yet normal 
function can be reinstated upon subsequent retransplantation 
to the hypothalamus (33). Therefore, there is considerable 
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evidence, albeit indirect, to suggest that the hypothalamus 
chronically exerts a trophic influence over pituitary cell 
types in addition to regulating acutely the synthesis and 
release of anterior pituitary hormones. 
In the present study, we investigated whether selected, 
identified hypothalamic factors, known to stimulate acutely 
the synthesis and/or release of several anterior pituitary 
hormones, could influence the proportions of GH or PRL cells 
in pituitary cultures from 5-day-old rats. This age group 
was chosen for study for two reasons. First, day 5 is the 
age at which the hypothalamo-hypophyseal portal system 
completes functional maturation. So this is the earliest 
age at which the hypothalamus could exert a major influence 
over pituitary function via the classical portal pathway 
(34). Therefore, we reasoned that pituitary cells might be 
particularly responsive to trophic agents at this time. 
Second, day 5 corresponds to the day after which PRL-
secreting cells first appear within the pituitary gland. 
Inasmuch as GH cells precede PRL cells during development, 
this is the youngest age at which both cell types would be 
present. By using reverse hemolytic plague assays to 
evaluate hormone release from single cells, we found that 
chronic (6-day) treatment of cultures with GRF, LHRH, TRH, 
CRF, or VIP induced differential changes in the proportions 
of GH- or PRL-secreting cells. For example, GRF and LHRH 
treatment resulted in an increase in the proportions of PRL 
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secretors and a commensurate decrease in the GH population. 
CRF increased the percentage of PRL cells without affecting 
the GH-secretors, while TRH reduced the percentage of both 
cell types; and VIP had no effect. Virtually identical 
results were obtained with pituitary cells from male or 
female donors. We believe that a nearly normal development 
of cells occurred in our control cultures over the 6-day 
period because the percentages of GH and PRL secreting cells 
present at the end of this culture period (11-day-old 
equivalents) were similar to those we reported earlier for 
10-day-old neonates (35.0 vs 34.06%, respectively, for GH; 
and 15.7 vs 13.06%, respectively, for PRL-releasors) (18). 
Thus our results indicate that hypothalamic factors have the 
capacity to influence the relative proportions of pituitary 
hormone-secretors, as well as the acute synthesis and 
release of adenohypophyseal hormones. However, our results 
provide little insight as to the mechanism(s) responsible 
for these effects. 
Hypothalamic factors could increase the percentage of 
cells that produce and release a given hormone in culture by 
at least three mechanisms: selective mitosis, differenti­
ation, or interconversion. Evidence supporting a role for 
mitosis was presented in several studies that showed 
hypothalamic factors to increase the mitotic rate of 
pituitary glands in situ (35) or of pituitary cultures (36). 
For example, Stratmann et al. (35) noticed a significant 
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increase in pituitary cell replication, as measured by the 
incorporation of tritiated thymidine, after 7- and 14-day 
treatments of intact male rats with TRH. Khar and coworkers 
(36) showed that rat hypothalamic extracts significantly 
increased the incorporation of tritiated thymidine into DNA 
by cultured rat anterior pituitary cells after 24 and 48h. 
However, LHRH, TRH, and somatostatin had no significant 
effect on the incorporation of tritiated thymidine by 
pituitary cells in their study. Documentation for a role of 
hypothalamic factors in the differentiation (conversion of 
non-hormone secretors to hormone secretors) of the anterior 
pituitary (26-28, 37, 38) was provided by Begeot et (26) 
who showed that LHRH stimulated immunoreactive lactotrope 
differentiation in cultured adenohypophyseal primordia. In 
addition, Gregerson and Campbell (37) reported that LHRH 
treatment of intact, hypophysectomized, orchidectomized, or 
hypophysectomized-orchidectomized hamsters, with pituitaries 
transplanted beneath the kidney capsule, increased the num­
ber of differentiated LH and FSH cells detected immunohisto-
chemically. Also, Hemming and coworkers (38) demonstrated 
that GRF was not necessary to induce fetal rat somatotrope 
differentiation in vitro, yet it did significantly increase 
the size of differentiated GH cells without affecting the 
time of appearance or number of cells that differentiated. 
Evidence in support of a role for specific hypothalamic 
agents in the functional interconversion of one type of 
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hormone secretor to another Is minimal at present. However, 
the results of several studies are suggestive of an inter-
conversion of pituitary cell types under the influence of 
estrogen (39, 40). The interconversion of somatotropes to 
mammotropes during the course of pregnancy was implicated in 
the study of Stratmann and coworkers (39), who used electron 
microscopic autoradiography to demonstrate that somatotropes 
labeled with tritiated thymidine could be induced to exhibit 
the ultrastructural characteristics of mammotropes by 
treating male rats with estrogen for 3 weeks. Previous 
studies from our laboratory (40) showed that estrogen 
treatment (6 days) of cultured pituitary cells from adult 
male rats caused an increase in the percentage of PRL-
secreting cells without affecting the percentage of GH-
releasing cells. When a sequential plaque assay was em­
ployed to identify not only cells that released GH or PRL, 
but also dual secretors (mammosomatotropes), we found an 
increase in the number of cells that released both GH and 
PRL and a commensurate decrease in the proportion that 
released GH only. These results suggested that a shift 
between GH and PRL cells could account, at least in part, 
for the increase in PRL cells observed. In summary, it is 
clear that there are precedents for specific hypothalamic 
factor-induced changes in anterior pituitary cell popula­
tions which are manifest via mitosis or differentiation. In 
addition the possibility exists that the interconversion of 
97 
one type of hormone secretor to another may occur upon 
chronic treatment of pituitary cells with these factors, as 
it does in the case of prolonged exposure to estrogen. 
Studies aimed at addressing which mechanism(s) was operative 
in the present investigation are currently underway in our 
laboratory. 
A corrollary issue which cannot be resolved from the 
present data is whether these hypothalamic factors acted 
directly on target cells to induce changes in GH and PRL 
cell populations or indirectly by stimulating other cells to 
produce factors which mediated their actions. Evidence to 
support the plausibility of indirect actions stem from the 
observation by Begeot et (27) that LHRH induction of 
lactotrope differentiation may be mediated in part through 
the -subunit of LH. Further evidence consistent with this 
idea comes from studies of anencephalic fetuses (12-14). 
Lactotropes will develop to a limited extent in anencephalic 
fetuses, where hypothalamic LHRH is lacking, and gonado-
tropes contain LH- oC but not the LH->8 subunit. Therefore, 
one could argue the LHRH is not an absolute requirement for 
the appearance of PRL cells, yet may contribute to the 
maintenance of these cells. Likewise, the possibility that 
the observed effects of secretagogues may be an apparent 
consequence of changes in the numbers of one or more adeno-
hypophyseal cell types not monitored in the present study 
cannot be resolved from the available evidence. 
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Taken together, we have shown that hypothalamic factors 
have the capacity to induce differential changes in the 
proportions of GH- and PRL-secreting cells. Our results 
further demonstrate that hypothalamic factors that do not 
normally affect the acute release of GH or PRL can exert a 
chronic influence (directly or indirectly) on the proportion 
of cells that secrete these hormones. One exciting inter­
pretation of these findings is that a given hypothalamic 
factor may subserve two completely dissociated functions: 
on the one hand it could act acutely on one pituitary cell 
to regulate the amount of hormone released, whereas on the 
other hand it might act chronically on the same or a 
different cell to influence the type of hormone secreted. 
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ABSTRACT 
A reverse hemolytic plague assay was used to 
investigate the mechanism(s) underlying sexual differences 
in GH release which evolve at puberty in rats. The percen­
tages of GH-secreting cells in 24h pituitary cultures from 
each sex were similar for pituitary donors up to 30 days of 
age (range = 38.9% to 41.7% of all cells in culture, n=3 
separate experiments) but decreased by day 50. The decrease 
was more striking for females (to 24.1 ± 0.3% mean ± SE) 
than for males (to 33.2 + 1.1%). However, owing to the 
greater increase in total pituitary cell number exhibited by 
female rats at this time, the absolute numbers of somato-
tropes recovered from male and female pituitaries were 
almost identical on 50 and 100 days of age. To assess the 
secretory capacities of individual somatotropes, we measured 
the sizes of plaques formed. In prepubertal rats (days 10-
30), the plaque areas under basal conditions were comparable 
for males and females at each age studied, and treatment 
with GH-releasing factor increased plaque sizes to approxi­
mately the same degree (10-fold) for both sexes at each age. 
However, by day 100, plaques that formed under both basal 
and stimulated conditions were consistently larger (P<0.01) 
for male than for female donors. Taken together, our 
results demonstrate that sexual differences in GH release 
are attributable to the secretory capacities of individual 
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somatotropes rather than to differences in the numbers of GH 
cells in pituitaries of male and female rats. 
108 
INTRODUCTION 
Sexual differences In pituitary content (1-4) and 
release (5-9) of GH appear around the time of puberty In 
rats, when values for males exceed those of females. How­
ever, It Is not known whether these differences are 
attributable to alterations In the absolute number of GH 
cells, to changes In the amount of GH released by each cell, 
or to both. In the present study, we attempted to distin­
guish between these possibilities by employing a reverse 
hemolytic plaque assay (10), which enabled analysis of GH 
release at the single cell level. To this end, we quanti­
fied the percentage of cells that released GH as well as 
measured the sizes of the plaques that formed around Indi­
vidual somatotropes In pituitary cultures from rats of each 
sex at various stages of development. Hormone release was 
evaluated In both the presence and absence of GH-releaslng 
factor (GRF). 
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MATERIALS AND METHODS 
Animals and cell culture 
All rats (Holtzman) used in this study were raised in 
our environmentally controlled (23C; lights on, 0600-1800h) 
animal facility and allowed continuous access to rat chow 
(Simonsen, Quimby, lA) and water. The day after birth was 
designated day 1 of neonatal life, and all animals were 
weaned on the morning of day 21. 
Anterior pituitaries were removed aseptically from rats 
killed by decapitation. At least eight adenohypophyses from 
10- and 20-day-old rats were pooled for a single dispersion, 
whereas a minimum of six glands were combined for 30-day-
olds. Pools of three or more glands were dispersed for 
older animals. All tissues were dissociated with trypsin as 
described previously (11), except that the dispersion time 
required to monodisperse anterior pituitaries of younger 
rats (Ih) was less than that for older donors (2h). Fifty-
and 100-day-old females were utilized without regard to the 
stage of the estrous cycle, and all 50-day and older males 
possessed viable sperm. Immediately after dispersion, cell 
counts were made with the aid of a hemocytometer, and cell 
yields were calculated. The cells were suspended in Dul-
becco's Modified Eagle's Medium [Grand Island Biological Co. 
(6IBC0), Grand Island, NY] containing 0.1% BSA (Fraction 5, 
Sigma Chemical Co., St. Louis, MO) and antibiotics (100 
ug/ml streptomycin sulfate, 100 U/ml penicillin G) (GIBCO), 
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seeded onto 35imn Petri dishes at a density of 2.5x10^ cells 
per dish and allowed to attach for 4h. Later, the initial 
medium was removed and replaced with Dulbecco's Modified 
Eagle's Medium containing 10% horse serum (GIBCO) and anti­
biotics as above for overnight culture. Pituitary cultures 
were maintained at 37C in a humidified atmosphere of 95% 
air-5% CO2. 
Placfue assays 
Standard plaque assaya for GH were conducted as 
described in detail elsewhere (10, 12-15). Briefly, 24h 
cultures of pituitary cells were recovered from 35mm Petri 
dishes after a mild retrypsinization, then mixed with 
protein-A coated ovine red blood cells (oRBCs) and infused 
into an incubation chamber. After the pituitary cells and 
oRBCs attached to the floor of the assay chamber as a mono­
layer, a 1:160 dilution of monkey-antirat GH serum (15) was 
infused into the chamber. Human pancreatic GRF 1-44 
(lxlO~^M) was also included at this step, when appropriate. 
Two hours later, a 1:40 dilution of guinea pig complement 
(GIBCO) was added, and maximal plaque development occurred 
within 50 min. The reaction was stopped by the infusion of 
fixative (1.8% glutaraldehyde in isotonic saline), and per­
centages of plaque-forming cells were measured with the aid 
of an Olympus IMT inverted microscope (Olympus Corp., New 
Hyde Park, NY). Pituitary cells were stained with toluidine 
blue before microscopic analysis to ensure detection of all 
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nonplaque-forming pituitary cells within the monolayer of 
oRBCs. 
The specificity of our GH antibody has been previously 
determined (15), and omission of antibody or complement 
completely abolished plaque formation in control experi­
ments. Analysis of variance, followed by Tukey's multiple 
range test, was used to assess statistical significance 
(16). 
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RESULTS 
The developmental patterns of GH-releasing cells in 
male and female rats are summarized in Figs. 4.1 and 4.2, 
respectively. Although male and female rats exhibited 
similar percentages of GH-releasing cells on days 10, 20, 
and 30, significant sexual differences were apparent by day 
50 and persisted at 100 days of age. Treatment with GRF 
(lxlO"^M) did not increase the percentages of GH-releasing 
cells at any age studied, indicating that the 2h antibody 
incubation was sufficient to detect maximal numbers of GH-
releasing cells under control conditions. Moreover, 
extending the incubation to 4h did not yield higher 
percentages (data not shown). 
Sexual differences in the percentage of GH plaque-
forming cells, which appeared between 30 and 50 days of age, 
are attributable in large part to the greater number of 
pituitary cells recovered from females. These sexual dif­
ferences were not apparent when the percentage of GH cells 
was adjusted for the number of pituitary cells recovered at 
the time of dispersion (Fig. 4.3). The absolute number of 
GH-secreting cells was similar for both sexes at 10 and 20 
days of age; however, by day 30 the absolute GH cell number 
reached levels found in 100-day-old adults. An apparent but 
statistically insignificant (P>0.05) decline in GH cell 
number was noted for both sexes at day 50. Thus, the 
absolute numbers of GH-secreting cells recovered from pitui-
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Ag« (D«ys) 
FIG. 4.1. Developmental patterns of GH-secreting cells in 
male rats. GH plague assays (2h antibody incu­
bations) were conducted on pituitary cells 
incubated in the presence or absence of GRF 1-44 
(IxlO'TM). The percentage of all cells in cul­
ture that released GH declined slightly after day 
30 to adult levels of 33.2%. Treatment with GRF 
did not increase significantly the number of 
somatotropes detected at any age studied. Shown 
in this and subsequent figures are the means and 
SE values of at least three separate experiments 
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FIG. 4.2. Developmental patterns of GH-secreting cells in 
female rats. GH plague assays were performed as 
described in Fig. 4.1. The percentage of GH-
releasing cells in controls declined considerably 
between days 30 and 50, reaching adult levels of 
24.1%. Again, GRF treatment did not influence 
the number of somatotropes detected at any age 
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FIG. 4.3. Quantity of GH cells recovered from pituitaries 
of male and female rats. The percentage of GH 
cells (from Figs. 4.1 and 4.2) was adjusted for 
the number of pituitary cells recovered at the 
time of dispersion to yield absolute numbers of 
GH-secreting cells per pituitary. Note that the 
numbers of GH cells recovered from pituitaries of 
male and female rats were approximately equal 
within each age studied 
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taries of male and female rats were approximately equal 
within each age studied. 
Sexual differences in the capacity of individual cells 
to release GH under basal and GRF-stimulated conditions are 
shown in Figs. 4.4 and 4.5, respectively. In both in­
stances, somatotropes from male rats showed an increasing 
capacity to release GH with age. In contrast, basal GH 
release from females reached a maximum at day 100, whereas 
GRF-stimulated GH release in the female was greatest at day 
20 and decreased slightly, but not significantly, 
thereafter. At each age studied, plaques surrounding GRF-
stimulated cells were significantly (P<0.01) larger ("10-
fold) than controls, regardless of the sex of the donor, 
significant sexual differences in plaque area were first 
apparent by day 50 and increased at day 100 in GRF-
stimulated cells, whereas significant differences in basal 
GH release were not detected until 100 days of age. 
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Control 
Male . 
Female 
FIG. 4.4. Average plague areas of GH-secreting cells under 
basal conditions from cultures of male and female 
pituitaries. Plague assays for GH were incubated 
for 2h in the absence of 6RF, and the size of 
plagues formed was used as an index of the amount 
of hormone released. Note that there was no sig­
nificant sexual difference in the size of plagues 
formed under basal conditions until day 100, when 
the difference was highly significant (P<0.01) 
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FIG. 4.5. Average plague areas of GRF-stlmulated GH-secre-
tlng cells from males and females. GH plaque 
assays were incubated for 2h in the presence of 
lxlO~^M GRF, and the size of plaques formed was 
used as an index of the amount of GH released. 
Plaque areas were, on the average, 10-fold larger 
than those measured previously for both sexes 
under.basal conditions (Fig. 4.4), and signifi­
cant (P<0.01) sexual differences appeared by day 
50 and increased at 100 days of age 
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DISCUSSION 
Sexual dimorphism of GH content in pituitaries of adult 
rats was first suggested by Jones et (3) on the basis of 
acrylamide gel electrophoresis of pituitary extracts. Using 
RIA, Birge and co-workers (1) confirmed this earlier report 
and extended it to include age-related changes in GH 
content. In addition, they observed that sexual differences 
in pituitary GH content arose at puberty. Subsequent 
studies by MacLeod et al. (6) and others (5, 9) have shown 
that the rate of GH synthesis is also much greater in 
pituitary glands from males when compared to females. 
Sexual differences in circulating GH levels have been 
difficult to quantify owing to the episodic pattern of 
release. However, Wehrenberg et (17) have shown that 
the in vivo response to GRF in adult male rats was signifi­
cantly greater than in females. Taken together, these 
findings indicate that pituitaries from adult male rats con­
tain more GH than those from females and possess the ability 
to release more of the hormone in response to GRF stimula­
tion. 
The issue of whether sexual differences in GH release 
are the consequence of discrepancies in the numbers of GH 
cells in male and females or are due to the capacities of 
individual cells to release GH is not clear. Immunocyto-
chemical analysis of rat pituitaries has revealed that the 
percentage of all pituitary cells containing GH is higher 
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for males than for females (10, 13, 15, 18). More recently, 
the percentage of GH-releaslng cells in pituitary cultures 
has been investigated with a reverse hemolytic plaque assay 
for GH, originally described by Frawley and Neill (10), In 
their paper, the percentage of GH-secreting cells in 
pituitary cultures from cycling females was about 30%, which 
was consistent with peroxidase-antiperoxidase immunocyto-
chemical estimates (28%). Using a similar technique, we 
have shown that GH-secreting cells in adult males (13, 15) 
comprise approximately one third of all cells in culture, 
which was in complete agreement with our immunocytochemical 
estimates obtained by the avidin-biotin-complex method. 
These findings have been confirmed in part by others (19). 
Thus, the percentage of GH-releasing (by plaque assay 
determinations) and GH-containing (immunocytochemical ob­
servations) cells appear to be greater in pituitary disper­
sions from male than from female rats. However, these 
findings do not provide a reliable estimate of the absolute 
number of somatotropes present, because pituitary glands 
from female rats contain more cells than those from males 
(20). Therefore, in the present study, we adjusted the pro­
portion of somatotropes for pituitary cell numbers and found 
that the absolute number of GH cells recovered from male 
and female pituitaries was almost identical within each age 
group studied. On the basis of these findings, we conclude 
that sexual differences in GH release are probably not due 
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to differences in somatotrope numbers. 
Having established that differences in somatotrope 
number could not account for the sexual dimorphism observed 
in GH release, we then investigated the possibility that the 
secretory capacities of individual somatotropes varied be­
tween sexes. This was accomplished by measuring the area of 
hemolysis surrounding single GH cells. That this approach 
provides a reliable index of the relative amount of GH 
released is supported by previous observations that plaque 
areas increased with incubation time and that stimulatory 
and inhibitory secretagogues exerted predictable effects on 
the sizes of plagues formed. Our present findings 
demonstrate clearly that plagues surrounding individual so­
matotropes from mature males are larger than those from 
females under both basal and GRF-stimulated conditions. Our 
observations are inconsistent with the hypothesis of Cronin 
and Rogol (21) that the presence of greater numbers of so­
matotropes in males, rather than differences in the 
secretory capacities per GH cell, is responsible for sexual 
differences in GH release. However, their hypothesis was 
based only on the reported differences in the percentages of 
GH cells in males and females and did not take into account 
the actual number of somatotropes present. 
The mechanisms responsible for sexual differences in 
the capacity of individual somatotropes to release GH are 
not completely understood. However, the results of the 
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present study demonstrate clearly that this divergence is 
initiated around the time of pubertal onset. These findings 
are consistent with earlier reports by others that 
differences between sexes in pituitary content and concen­
tration (1-4) of GH as well as plasma levels of the hormone 
evolve at the time of sexual maturation. There are several 
lines of evidence to suggest that gonadal steroids, which 
increase at puberty, regulate this phenomenon. First, it 
was shown by Birge et aJL. (1) that castration of male rats 
decreased pituitary GH content. In addition, these inves­
tigators and others (3) showed that ovariectomy increases 
pituitary content and concentration of GH to levels higher 
than intact or sham-operated females, lower than intact or 
sham-operated males, and very similar to the levels seen in 
pituitaries of castrated male rats. This suggests that tes­
tosterone enhances and estrogen depresses GH synthesis and 
release. Second, treatment of intact or gonadectomized male 
rats with estrogen (1, 2) decreased pituitary content of GH, 
whereas treatment of female rats with testosterone (1, 22, 
23) had the opposite effect. In addition, Wehrenberg et al. 
(17) reported that pretreatment of intact and gonadectomized 
male rats with testosterone increased the pituitary response 
to GRF whereas pretreatment of gonadectomized females with 
estrogen had no effect on the response to GRF, and concluded 
that androgens, but not estrogens, play an active role in 
modulating pituitary responsiveness to GRF in vivo. This 
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idea is in concert with the view of Ojeda and Jameson (24) 
that androgens may play a more important role in stimulating 
GH release in rats than estrogen. Finally, in vitro studies 
(5, 6, 9) on cultures of pituitary cells derived from 
immature and mature rats of each sex yielded results which 
are entirely consonant with in vivo findings. 
In summary, we have shown that sexual differences in GH 
release are attributable to the secretory capacities of 
individual somatotropes rather than to differences in the 
absolute numbers of GH cells in pituitaries of male and 
female rats. These differences in secretory capacities 
probably are due to the influences of gonadal steroids. 
Whether this dimorphism at the pituitary level is also a re­
flection of sexual differences in hypophysiotropic input (8, 
25) remains to be determined. 
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ABSTRACT 
It is generally accepted that hypothalamic somatostatin 
and hepatic IGF-I/somatomedin-C act directly at the pitui­
tary level to inhibit GH release, but it is not known 
whether all somatotropes are responsive to these agents. In 
the present study, we used a reverse hemolytic plague assay 
to compare the acute (8h) effects of somatostatin and IGF-I 
on the release of GH from individual cells in 24h cultures 
of male rat pituitaries. Treatment with these factors 
caused comparable dose-dependent decreases in both the rate 
of plague formation and the percentage of cells which re­
leased GH. In 8h incubations, maximal (10""®M) doses of IGF-
I or somatostatin alone decreased the percentage of GH-
releasing cells to approximately the same degree (from 34.4% 
in controls to 29.7% and 28.4% respectively), yet the 
effects of these factors were additive when both agents were 
applied to the same cells (to 24.5%). When we analyzed the 
sizes of plagues (an index of the amount of hormone released 
per cell) which resulted from these treatments, we noted 
that somatostatin was a much greater suppressor (to 11% of 
control value) of GH release than IGF-I (60% of controls). 
Coincubation with lO^^M GRF had no effect on the percentage 
of GH-releasing cells at 8h, but completely overrode the 
inhibitory effect of IGF-I on plague size without affecting 
the somatostatin-induced decrease in this regard. Taken 
together, these data suggest that IGF-I and somatostatin 
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act, at least in part, on separate subpopulations of rat 
somatotropes. Somatostatin is a much more effective inhib­
itor of total GH release than IGF-I, and appears to affect 
most, if not all, somatotropes. In contrast, IGF-I acutely 
inhibits GH release (prevents plague formation) from some 
somatotropes, but does not seem to affect the remaining GH 
cells. 
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INTRODUCTION 
Numerous studies have documented the ability of 6H to 
regulate Its own secretion through a short-loop feedback 
mechanism Involving hypothalamic somatostatin (1-8). Yet, 
until recently, the existence of a long-loop feedback mech­
anism of GH release had not been Identified. In the last 
few years, several studies have demonstrated the ability of 
IGF-I/Sm-C to regulate GH secretion (9-13). While the dy­
namics of IGF-I Inhibition of GH release are not completely 
defined, It Is generally accepted that this factor as well 
as somatostatin can act directly at the pituitary level to 
Inhibit GH release. 
Earlier reports by ourselves and others have documented 
the presence of functional subpopulatlons among somatotropes 
In rats (14-18). Such heterogeneity has been revealed pri­
marily (14-16, 18) by use of reverse hemolytic plague 
assays, which enable analysis of hormone release at the 
single cell level. In the present study we employed this 
technique to determine whether somatotropes from male rats 
are differentially responsive to somatostatin and IGF-I. 
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MATERIALS AND METHODS 
Animals and cell culture 
All rats (Holtzman, Madison, WI) used in this study 
were maintained in our environmentally controlled animal 
facility (23C; lights on from 0600-1800h) and allowed 
continuous access to rat chow (Simonsen, Quimby, lA) and 
water. Anterior pituitaries from 100-120 day-old adult male 
rats (400-450 g BW) were obtained aseptically following 
decapitation, dispersed with trypsin by the method of Hymer 
et al. (19), and established in primary culture as described 
previously (16). In short, monodispersed cells were seeded 
onto 35 mm plastic dishes at 3 x 10® cells/dish and cultured 
overnight in Dulbecco's Modified Eagles Medium containing 
10% horse serum and antibiotics. A minimum of 3 pituitaries 
were pooled for each dispersion. 
Plague assavs 
The reverse hemolytic plaque assay for GH was conducted 
according to procedures detailed elsewhere (16). Briefly, 
monodispersed cells obtained after a short retrypsinization 
of 24h cultures of pituitary cells from adult male rats were 
mixed with protein A-coated ovine erythrocytes (oRBCs) to 
achieve final concentrations of 2.5 x 10® pituitary cells/ml 
and 6% oRBCs. This mixture was then infused into assay 
chambers and allowed to attach for 45 min before washing 
excess (unattached) cells out of the chambers. Our monkey 
anti-rat GH serum (16) diluted 1:160 in assay medium was 
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then Infused Into the chambers by itself or together with 
either growth hormone-releasing factor (GRF, 1-44, 10~®M, 
Peninsula Laboratories, Belmont, CA), somatostatin (SS, 10" 
to lO^Tw, Sigma, St. Louis, MO), or recombinant human 
IGF-I (10-10 to 10-7M, AMGen, Thousand Oaks, CA). For time-
course studies, various doses of somatostatin or IGF-I were 
incubated with antibody and secretagogue for 1 to 8h. In 
contrast, single 8h incubations were used in those studies 
designed to evaluate the combined effects of these sub­
stances. In all cases, the antibody incubation was followed 
by a 50 min treatment with a 1:40 dilution of guinea pig 
complement (Grand Island Biological Company, GIBCO, Grand 
Island, NY) followed by fixation with 1.8% glutaraldehyde 
(Sigma, St. Louis, MO) in saline. The pituitary cells 
within the monolayers were then stained with toluidine blue 
to facilitate the quantification of the percentage of GH 
plaque forming cells as well as the average size of the 
plaques that formed. An inverted tissue culture microscope 
was used to analyze the results. At least 300 cells were 
counted on each slide and a minimum of 2 slides were ana­
lyzed for each treatment from a single experiment (of 3 
separate experiments). The specificity of our GH antiserum 
and the validity of the plaque assay for detecting GH 
secretion from cultures of male rat pituitary cells have 
been demonstrated previously (16). 
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Statistical analysis 
The statistical significance of differences among 
experimental groups was evaluated by one-way analysis of 
variance followed by Tukey's multiple range test (20). 
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RESULTS 
The effects of somatostatin and IGF-I on the rate of GH 
plaque development are illustrated in Figs. 5.1 and 5.2, re­
spectively. In both cases, the percentage of all cultured 
cells in controls that formed plaques increased gradually 
with incubation time and reached a maximum by 4h. Overall, 
each dose of either agent decreased significantly the rate 
of plaque development when compared with the appropriate 
control, and this effect persisted in a dose dependent man­
ner even after 8h. 
The differential effects of IGF-I and somatostatin on 
two indices of GH plaque development are summarized in Fig. 
5.3. After an 8h incubation, maximal doses (10"®M) of IGF-I 
or somatostatin alone or in combination significantly 
(E<0.05) decreased both the percentage of plaque formers and 
the average size of GH plaques that developed (an index of 
the amount of hormone released). Interestingly, although 
these factors decreased the percentage of GH-secreting cells 
to approximately the same degree when tested separately, 
there was a statistically significant (p<0.05) additive 
effect when these secretagogues were applied together to the 
same monolayers. Coincubation with a maximal dose of GRF 
(10~®M, for dose response, see ref. 16) did not have a sig­
nificant (e>0.05) effect on the percentages of GH-secreting 
cells detected in any of the aforementioned treatments. In 
contrast, coincubation with GRF significantly (p<0.01) 
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FIG. 5.1. Effect of somatostatin on the rate of GH plaque 
formation in pituitary cell cultures from male 
rats. Plaque assays were performed by incubating 
pituitary cells with antibody in the presence or 
absence of somatostatin (lxlO~^° to lxlO~^M) for 
1, 2, 4, 6, or 8h. Plaques were then developed 
during a 50 min incubation with complement and 
the reaction was terminated by the addition of 
fixative. Shown here are the results of a single 
experiment which is representative of three sep­
arate experiments performed on different batches 
of dispersed cells. Each point represents the 
mean ± SE of determinations made on three sepa­
rate plaque assay slides in which at least 200 
cells were counted per slide. There was no 
significant (E>0.05) difference in the percent 
inhibition noted between separate experiments; 
however, the actual percentages of GH plaque-
forming cells varied within 2-4% 
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FIG. 5.2. Effect Of IGF-I on the rate of GH plague forma­
tion in pituitary cell cultures from male rats. 
Plague assays were performed as described in Fig. 
5.1 except that IGF-I (1x10-1° to IxIQ-^m) was 
incubated with the pituitary cells. Again, this 
is a representative example of three separate 
experiments, and as in Fig. 5.1, there was no 
significant difference in the percent inhibition 
between separate experiments. Each point 
represents the mean ± SE of determinations made 
on three separate plague assay slides (200 cells 
counted/slide) 
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FIG. 5.3. Differential effects of I6F-I and somatostatin on 
the percentage of 6H plaque-forming cells (left) 
and the average plaque area (right). Single 8h 
incubations with antibody alone or in combination 
with maximal (10~®M) doses of IGF-I, somatosta­
tin, and/or GRF were utilized. Each point repre­
sents the mean ± SE of three separate experi­
ments. For percentage estimates, 200 cells were 
counted per slide, and a minimum of two slides 
from each experiment were analyzed per treatment. 
For plaque size determinations, 100 plaques were 
measured/slide, and again at least two slides 
were analyzed from each experiment per treatment 
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increased the average GH plaque area on IGF-I inhibited 
monolayers, yet had absolutely no effect (p>0.05) on the 
average plague area of any somatostatin treated monolayers. 
Finally, somatostatin alone or in combination with IGF-I was 
significantly (p<0.01) more effective in decreasing the 
average size of GH plaques than IGF-I alone. 
The frequency distribution of GH-plaque sizes resulting 
from the treatments outlined above are plotted in Fig. 5.4. 
Note that all treatments involving somatostatin shifted 
plaque size distributions toward smaller plaques whereas 
IGF-I alone had little effect on this variable. Treatment 
with GRF did not effect the frequency distribution for soma-
tostatin-inhibited cells, yet coincubation of monolayers 
with GRF and IGF-I resulted in a bimodal frequency distribu­
tion of plaque sizes. 
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FIG. 5.4. Frequency distributions of GH plague sizes after 
IGF-I and somatostatin treatment. Plague size 
distributions were plotted from the same data 
used to calculate average plague areas in Fig. 
5.3 
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DISCUSSION 
The secretion of GH is under dual control, stimulatory 
as well as inhibitory. The two predominant factors which 
comprise the inhibitory component of GH regulation are hypo­
thalamic somatostatin and IGF-I, also referred to as somato-
medin-C (21), which is produced by the liver in response to 
GH. Somatostatin exerts a striking inhibition of basal or 
stimulated GH release within 10 minutes of exposure to 
pituitary cells in vitro (22). However, the efficacy and 
dynamics of IGF-I inhibition of GH release are less clearly 
defined. Berelowitz et (9) and Brazeau and coworkers 
(10) found no effect of Somatomedin-C (Sm-C) on basal GH 
release in either acute (4h) or chronic (24h) incubations in 
vitro. The latter group however, reported that Sm-C de­
creased GRF-stimulated GH release in both 4 and 24h treat­
ments, whereas the former group found no acute effect of the 
peptide on GRF-stimulated release but noted a 90% decrease 
after 24h. Conversely, Goodyer et (13) reported that a 
semipurified preparation of IGF peptides decreased both 
basal and theophylline-stimulated GH release during acute 
(3-4h) exposure, but only extremely high concentrations were 
effective at 24h. Therefore, although the evidence concern­
ing acute vs chronic effects of somatomedins on GH release 
is controversial, it is clear that both somatostatin and 
somatomedins can act directly at the pituitary level to 
inhibit GH release. 
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In the present study we used a reverse hemolytic plague 
assay to compare the acute (up to 8h) effects of somatosta­
tin and IGF-I on the release of GH from individual pituitary 
cells. We found that these factors caused comparable dose-
dependent decreases in the rate of GH plague formation as 
well as similar decreases in the percentage of cells which 
released the hormone. When maximal (10~%) doses of these 
factors were utilized in a single 8h incubation, each secre-
tagogue reduced the percentage of GH-plague-forming cells to 
approximately the same degree. Surprisingly however, when 
maximal doses of IGF-I and somatostatin were coincubated on 
the same monolayers, we found a further decrease in the 
percentage of GH-secretors which was quantitatively equal to 
the sum of the decrements noted when each agent was tested 
alone. Thus the effects of these two factors on the percen­
tage of GH cells are additive. Furthermore, treatment with 
GRF (10~®M) did not reverse this additive inhibition. 
Therefore, under both basal and stimulated conditions, IGF-I 
and somatostatin each exert a striking inhibition of secre­
tion (preventing plague formation) by some but not all soma-
totropes, and the subpopulations of somatotropes affected by 
these factors appear to be different. This latter conclu­
sion is based on our observation that the combination of 
maximal doses of these factors produce an additive inhibi­
tion of GH plaque formation. 
In the present study, we also analyzed the effects of 
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somatostatin and I6F-I on the sizes of GH plaques that 
formed. The rationale for this approach was that plaque 
size provides a reliable index of the relative amount of 
hormone released by each cell (18). We found that although 
each treatment alone significantly (p<0.01) reduced the 
average size of plaques that formed (and therefore the 
amount of GH released), a maximal dose of somatostatin was 
much more effective in this regard than a comparable amount 
of IGF-I. On those monolayers simultaneously exposed to 
maximal doses of both agents, the resulting average plaque 
size was identical to that found on monolayers treated with 
somatostatin only. Therefore, the effects of IGF-I and 
somatostatin on this index of GH release were not additive. 
Taken together, these data show that somatostatin is a much 
more potent inhibitor of GH release than IGF-I, and is prob­
ably responsible for a majority of the acute input exerted 
at the hypophyseal level. Moreover, somatostatin appears to 
affect all GH cells; it severely inhibits release from some 
cells (prevents plaque formation) and reduces the amount 
released (plaque size) by the rest. In contrast, IGF-I in­
hibits GH plaque development by some cells, but doesn't 
severely influence the amount released (plaque size data) by 
those cells that do form plaques. 
The stimulatory effect of GRF on the average size of GH 
plaques seen when compared with controls, was completely 
overridden by combined treatment with somatostatin. In 
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contrast, when I6F-I and GRF were coincubated on the same 
monolayers, the resulting plague sizes were similar to GRF-
only treated monolayers. Therefore, the cells which form 
plagues in the presence of IGF-I are fully responsive to 
GRF, yet somatostatin renders cells that form plagues in its 
presence unresponsive to GRF. Again, unlike IGF-I, somato­
statin influences all somatotropes in this regard. 
In order to more clearly delineate the noted effects of 
these secretagogues on the amount of GH released/cell, we 
constructed freguency distributions of plague sizes for 
each treatment employed. This approach revealed that soma­
tostatin treatment shifted plague areas towards smaller 
plagues whereas IGF-I had little effect on the distribution 
of plague sizes. As expected from the results described 
above, treatment with GRF had no effect on plague size dis­
tributions in the presence of somatostatin, yet when IGF-I 
treated cells were simultaneously exposed to GRF, plague 
size distributions shifted towards larger plague areas pro­
ducing a bimodal distribution. Taken together, these 
results support further our conclusions that IGF-I and soma­
tostatin act in part on separate subpopulations of somato­
tropes, that somatostatin is a much more potent inhibitor of 
GH release than IGF-I and appears to affect most, if not 
all, somatotropes, and that IGF-I severely inhibits GH 
release (prevents plague development) by only a fraction of 
somatotropes. 
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The results of this study raise three very interesting 
questions. First: Is the acute inhibition of GH release by 
IGF-I an all or none phenomenon? More specifically, does 
IGF-I affect only those somatotropes which account for the 
decreased percentage of GH-releasing cells in 8h treatments? 
The observations that the distribution of plaque sizes is 
similar between IGF-I inhibited monolayers and controls and 
that those cells which do secrete GH in the presence of this 
factor are entirely responsive to GRF are consistent with an 
all or none response. The second question raised by the 
present data relates to possible differences in the mechan­
isms by which -IGF-I and somatostatin act. Do the intracel­
lular mechanisms which mediate the inhibition of GH release 
differ in somatostatin and IGF-I responsive somatotropes? 
In siigport of such a possibility is the recent observation 
by Sheppard et (23) that somatostatin decreased cAMP 
levels as well as GRF-stimulated GH release whereas IGF-I 
had no effect on cAMP levels while still inhibiting hormone 
release. The third and final question was inspired by the 
proposal of Sheppard et al. (23) that IGF-I inhibits 
preferentially the release of newly synthesized GH whereas 
somatostatin acts on both stored and recently synthesized 
hormone. This view was based on their finding that cyclo-
heximide abolished IGF-I inhibition of GH release but had no 
effect on that caused by somatostatin. Thus, the specific 
question related to our data is as follows: Do IGF-I and 
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somatostatin responsive cells differ in the age of secreted 
hormone? Recent evidence that IGF-I reduces GH mRNA levels 
as well as GH secretion (24) might support this idea. 
Studies aimed at addressing the cell specificity as well as 
the intracellular mechanisms of IGF-I and somatostatin 
action on somatotropes are currently underway in our 
laboratory. 
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ABSTRACT 
An in vitro bioassay (based on detection of casein 
release from isolated mammary cells by reverse hemolytic 
plaque assay) was used to detect a lactogenic factor 
secreted by liver tissue from suckled rats. This material 
stimulates casein release in the absence of added PRL and is 
actually more potent than PRL in this regard. The sub­
stance (s) possesses the following additional character­
istics: 1) it is released from liver tissue of lactating 
but not virgin female or male rats; 2) when tested together 
with PRL, its effects are additive rather than synergistic; 
and 3) unlike PRL, it does not increase the proportion of 
mammary cells committed to casein release. These findings 
are consistent with the possibility that a Liver Lactogenic 
Factor may mediate, at least in part, the lactogenic 
component of PRL's action. This functional relationship may 
be similar to that which exists between GH and the somato­
medins . 
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INTRODUCTION 
Recent evidence from Nicoll's group suggests that liver 
tissue from lactating rats produces a substance that is 
mitogenic in both the pigeon crop-sac bioassay and a rat 
mammary expiant assay (1-3). This factor is reported to 
augment the response of the crop sac to PRL, yet is not 
mitogenic when used alone in this bioassay system. Hence, 
the factor has been termed "synlactin" because it synergizes 
with PRL to enhance mitogenic activity. 
In the present study, we attempted to resolve whether 
the liver also produces a substance(s) which augments the 
lactogenic component of PRL's action. To this end, we eval­
uated the lactogenic potency of rat liver incubates using a 
novel casein plague bioassay (4). This system is based on 
the ability of lactogenic substances, such as PRL, to induce 
the secretion of casein by cultured mammary cells. Casein 
release, in turn, is measured by a reverse hemolytic plaque 
assay which is specific and extremely sensitive. Here we 
provide evidence that liver tissue from lactating rats 
releases a factor which stimulates the secretion of casein 
by isolated mammary cells in culture. 
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MATERIALS AND METHODS 
All rats were purchased from Holtzman Co. (Madison, WI) 
and maintained under conditions of constant temperature and 
controlled photoperiod (lights on 0600-1800h) and were pro­
vided with rat chow and tap water ad libitum. The lactating 
rats were derived from virgin females bred in our own facil­
ity. Litter size was standardized to 8 pups on the day of 
birth. 
Slices of liver tissue (0.3-0.5mm thick, approximately 
1.Og), prepared with a Statie-Riggs hand microtome (3), were 
placed in a Spinner's Suspension Flask containing 20ml Dul-
becco's Modified Eagle's Medium supplemented with 0.1% BSA 
and antibiotics (henceforth referred to as medium) at 
concentrations described previously (4). The tissue was in­
cubated with constant slow stirring (the impeller bar was 
placed above the slices) for 3h at 37C in an atmosphere of 
95% air: 5% CO2. At the end of the incubation, the medium 
was passed through Whatman No. 1 filter paper (Whatman Ltd., 
Maidstone, England). 
The presence of lactogenic activity in the filtrate was 
evaluated with a casein plague bioassay system described in 
detail elsewhere (4). In this assay, casein-secreting 
mammary cells induce the formation of microscopically iden­
tifiable plagues (zones of hemolysis) when incubated with 
protein-A-coated ovine erythrocytes (oRBCs) in the presence 
of casein antiserum and complement. Briefly, assay 
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incubation chambers containing monolayers of mammary cells 
(from day-10 lactating rats) and oRBCs were preincubated for 
17h in the presence or absence of liver incubation medium 
either alone or in combination with rat PRL (NIADDK-B5). 
The chambers were then flushed with fresh medium and incu­
bated with rabbit anti-rat casein serum (1:500) for 2h. 
Plaques were developed during a subsequent 50 min incubation 
with a 1:60 dilution of guinea pig serum (a source of 
complement). After staining with toluidine blue, plaque de­
velopment was quantified (with the aid of a microscope) by 
determining the percentage of cells that formed plaques (% 
PFC) or the sizes of plaques that developed. 
Statistical significance of differences between treat­
ment groups was determined by Student's t test (5). 
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RESULTS 
A stimulatory effect of liver medium filtrate on casein 
secretion by rat mammary cells can be seen by examining the 
photomicrographs in Figure 6.1. The degree of hemolysis in 
proximity to mammary cells exposed to liver medium from 
lactators was consistently greater than that of controls. 
Shown in Figure 6.2 is a comparison of the quantitative 
effects of liver incubation medium and rat PRL on two vari­
ables of casein plaque development. Treatment with rat PRL 
evoked dose-related increases in both the percentage of mam­
mary cells that formed plaques and the average size of 
plaques that developed. In contrast, dilutions of liver 
incubation medium from lactating rats had absolutely no 
effect on the proportion of casein plaque formers but caused 
graded increases in average plaque area. In fact, maximally 
effective dilutions of liver incubation medium were much 
more potent than comparable doses of PRL when only the rel­
ative amount of casein released per cell (plaque size) was 
considered. Incubation medium that bathed kidney tissue 
from lactating rats and liver tissue from male or virgin fe­
male rats as well as insulin-like growth factor-I were also 
tested and found to have no activity in this assay system 
(data not shown). 
The combined effects of rat PRL and the lactogen found 
in liver incubation medium are illustrated in Figure 6.3. 
Coincubation with liver medium from lactators did not alter 
159 
FIG. 6.1. Effect of liver medium filtrate (from day-10 
lactators) on casein release by rat mammary cells 
(photomicrographs x 40). Plaque assay chambers 
containing monolayers of rat mammary cells and 
oRBCs were preincubated for 17h in the absence 
(left) or presence (right) of liver incubation 
medium diluted 1:32. This was followed by a 
plague assay for casein. Note that the sizes of 
plaques (relative amount of casein released per 
cell) are much larger in the liver medium-treated 
monolayer 
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FIG. 6.2. Differential effects of rat PRL and liver incu­
bation medium on casein plague development. 
Monolayers of rat mammary cells and oRBCs were 
first exposed for 17h to graded doses of rat PRL 
or serial dilutions of liver incubation medium 
and then subjected to a casein plague assay as 
described earlier. Both the % PFC and the sizes 
of plagues that developed were guantified on the 
same monolayers. Rat PRL had a stimulatory 
influence on each of these variables, whereas 
liver medium augmented only plague size. In this 
and the following figure, results are presented 
as the mean + SE of triplicate determinations in 
a single experiment which is representative of at 
least 3 separate experiments 
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effects of control medium alone, or liver medium 
only, are represented as 0 pg/ml rat prolactin. 
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the effect of PRL on the percentage of casein plaque 
formers. Conversely, plaque size was augmented by combined 
treatments, and this interaction appeared to be additive. 
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DISCUSSION 
We recently reported that PRL augments casein 
production by Increasing both the proportion of mammary 
cells that secrete the milk protein and the amount of casein 
released by each cell (4). The results of the present study 
confirm these earlier observations and also provide evidence 
that liver tissue from lactatlng rats produces a substance 
which partially mimics the actions of PRL; it Increases the 
amount of casein released per mammary cell without affecting 
the number of cells committed to casein release. In fact, 
the liver material is even more potent than rat PRL Itself 
in evoking the release of casein from individual cells. Be­
cause the presence of this liver lactogen is associated with 
a physiologic state of elevated PRL secretion (lactation), 
it is tempting to propose that it may serve as an extracell­
ular mediator of PRL's action. This functional relationship 
would be analogous to that which exists between GH and the 
somatomedins (6, 7). The physiologic significance of a 
selective mediator of PRL's effects has yet to be eluci­
dated. However, one possibility is that the existence of 
such a liver lactogen may provide a mechanism by which the 
lactogenic and mammary mitogenlc actions of PRL can be dis­
sociated and perhaps differentially regulated. 
The lactogenic material currently under investigation 
in our laboratory bears similarities as well as differences 
to the "synlactin" activity described by Nicoll's group 
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(1-3). Both factors are similar in that they are released 
by liver tissue and that their presence is associated with 
elevated (but not basal) states of PRL secretion. On the 
other hand, there are also fundamental differences, the most 
obvious of which derives from the divergent biological end-
points used to characterize these factors (namely mammary 
mitogenic vs. lactogenic activities). Another important 
distinction relates to the degree of functional autonomy 
exhibited by these factors. "Synlactin" is reported to aug­
ment PRL's action but to have little activity of its own, 
whereas the liver lactogen is very potent by itself and 
interacts with PRL in an additive rather than a synergistic 
manner. While these comparisons do not preclude the 
possibility that "synlactin" and the substance under study 
by our group are identical chemical entities, we believe the 
differences are sufficient to justify considering it as a 
separate substance. Therefore, we propose that our active 
principle be called Liver Lactogenic Factor, at least until 
the precise chemical nature of both substances is estab­
lished. 
In summary, our results demonstrate that liver tissue 
from lactating rats produces a potent lactogen and raise the 
possibility that this substance(s) could in part mediate the 
lactogenic component of PRL action. The issue of whether 
this Liver Lactogenic Factor and the "synlactin" described 
by others are one and the same molecule cannot be resolved 
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unequivocally until both activities are isolated and 
characterized. 
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SUMMARY AND CONCLUSIONS 
The development of the radioimmunoassay (RIA) for the 
measurement of minute quantities of hormone, marked the 
beginning of a new era in endocrine research. This new 
level of sensitivity created more questions than provided 
answers. By combining this technique with others which en­
abled the enrichment or purification of specialized endo­
crine cell types, the concept of functional heterogeneity 
within cell types was conceived. The RIA also allowed the 
characterization of stimulatory and inhibitory control of 
hormone release from cell populations. However, the 
molecular and cellular basis of this heterogeneity and dif­
ferential regulation of hormone release remained beyond 
grasp because RIA measures only the combined amount of 
hormone released by a large population of cells. 
The existence of mammosomatotropes in addition to 
classical mammotropes and classical somatotropes provides a 
good example of such cellular heterogeneity. Despite the 
abundance of circumstantial evidence suggestive of a 
functional overlap between GH and PRL cells, it has 
generally been accepted that these hormones are secreted by 
separate and distinct cell types within the pituitary gland. 
This view was based on tinctorial, ultrastructural, and 
immunocytochemical evidence that GH and PRL were stored 
within separate cells (1-3). However, with the development 
by Frawley and Neill (4, 5) of reverse hemolytic plaque 
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assays for GH and PRL, a more direct approach to this 
problem became possible. These assays, which are based on 
antibody-directed, complement-mediated lysis of erythrocytes 
in the vicinity of hormone secretors, enable direct micro­
scopic visualization of hormone release from individual 
pituitary cells in culture. By performing sequential plaque 
assays for two different hormones on the same pituitary 
cells, it is possible to identify cells which release more 
than one hormone at the same time. 
By combining the use of plaque assays with immunocyto-
chemistry, it was shown that the capacities of fetal somato-
tropes to store GH and release it under basal and regulated 
conditions are attained in large part within a 24h period 
between days 18 and 19 of development. However, because not 
all GH containing cells on day 19 are competent to release 
the hormone under basal or stimulated conditions, it follows 
that the intracellular mechanisms responsible for the syn­
thesis and storage of GH and the capacity to release the 
hormone probably evolve sequentially rather than concurrent­
ly during development. 
The developmental appearance of PRL-releasing cells was 
found to occur approximately one week (day 4 of neonatal 
life) after the differentiation of GH cells (day 19 of 
gestation). Subsequently, by utilizing a sequential version 
of the plaque assay, it was shown that virtually all of 
these initial PRL-secreting cells also released GH. These 
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findings raise the possibility that GH cells give rise to 
PRL cells during development and that the mammosomatotrope 
may be a transition cell type which may further differen­
tiate into a cell type which releases PRL only. Of course, 
acceptance of this view will require the demonstration that 
specific cells committed exclusively to GH release on day 3 
can be induced to release PRL on day 4, and that cells which 
release both hormones can be induced to release only PRL. 
Early studies of natural and experimental anencephaly 
(6-8) and investigations with anterior pituitary anlagen 
cultured in vitro (9-15) have suggested a role for the 
hypothalamus in the differentiation of the adenohypophysis. 
By treating pituitary cultures from S-day-old rats of each 
sex with specific hypothalamic regulatory factors for six 
days, it was demonstrated that these factors (some of which 
do not normally affect the acute release of GH or PRL) can 
exert a chronic influence on the proportion of cells that 
secrete these hormones. One exciting interpretation of 
these findings is that a given hypothalamic factor may 
subserve two completely dissociated functions; on the one 
hand, it could act acutely on one pituitary cell to regu­
late the amount of hormone released, whereas on the other 
hand, it might act chronically on the same or a different 
cell to influence the type of hormone released. When taken 
together with the studies mentioned above, it is tempting to 
speculate on the involvement of these factors in the 
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interconversion of GH- and PRL-releasing cells via the 
mammosomatotrope. 
In the first three studies described in this disserta­
tion, there was no sexual difference found in either the 
ontogeny of acidophilic cell types or the responses of these 
cells to chronic treatment with hypothalamic factors. How­
ever, sexual differences in GH release have been reported to 
appear at puberty in the rat, and these differences persist 
in the adult (16-24). It was suggested by Cronin and Rogol 
(25) that these differences were due to greater numbers of 
somatotropes in males than in females. However, their 
hypothesis was based only on the reported differences in the 
percentages of GH cells in males and females and did not 
take into account the actual number of somatotropes present. 
By utilizing GH plague assays and adjusting the proportion 
of somatotropes detected for the different pituitary cell 
numbers in cultures from males and females, it was demon­
strated that the absolute number of GH cells recovered from 
each sex was almost identical within each age group studied. 
Furthermore, by analyzing the average plague area surround­
ing individual somatotropes (an index of the amount of GH 
released), it was confirmed that sexual differences in GH 
release are attributable to the secretory capacities of 
individual somatotropes rather than to differences in the 
absolute numbers of GH cells in pituitaries of male and 
female rats. Whether this sexual dimorphism at the 
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pituitary level is due primarily to the influence of gonadal 
steroids or sexual differences in hypophysiotropic input, 
remains to be determined. 
The question of whether there is functional heterogene­
ity among pituitary cells within a given cell type is very 
important, yet answers have not been forth coming because of 
technical limitations. The ability to measure hormone 
release from individual cells using reverse hemolytic plaque 
assays has made studies on the functional heterogeneity 
within pituitary cell types possible. In chapter five, this 
extremely sensitive technique was used to investigate 
differential responsiveness of GH cells to the inhibitory 
effects of somatostatin and IGF-I. By utilizing maximal 
doses of each agent, it was possible to define an additive 
effect of these factors on the number of GH-releasing cells, 
which implies that these factors act at least in part on 
separate subpopulations of rat somatotropes. Moreoever, by 
comparing the relative amount of GH released after each 
treatment alone or in combination with the stimulatory se-
cretagogue GRF, it was noted that somatostatin is a much 
more potent inhibitor of GH release than IGF-I and appears 
to affect most, if not all, somatotropes, and that IGF-I 
severely inhibits GH release (prevents plaque formation) by 
only a fraction of somatotropes, and doesn't seem to affect 
the others. Three very interesting questions were raised by 
this study; 1) Is the acute inhibition of GH release by IGF-
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I an all or none phenomenon?, 2) Do the intracellular mech­
anisms which mediate the inhibition of GH release differ in 
somatostatin and I6F-I responsive somatotropes?, and 
finally, 3) Do I6F-I and somatostatin responsive cells 
differ in the age of secreted hormone? As more and more 
laboratories begin employing new, extremely sensitive 
techniques such as the plague assay, the answers to these 
questions will provide new insight into the mechanisms and 
consequences of differential regulation of hormone release. 
In the last chapter, a reverse hemolytic plaque assay, 
based on the detection of casein release from isolated 
mammary cells, was used to identify the presence (in crude 
liver incubates) of a lactogenic factor in the liver of 
lactating rats. The presence of this factor in liver seemed 
to be correlated to states of high physiologic levels of 
PRL. The lactogenic activity of this factor differed from 
PRL, in that it stimulated the amount of casein released per 
mammary cell, yet had no influence on the number of cells 
committed to casein release. Because the substance was 
active in the absence of added PRL and did not synergize 
with PRL, it is regarded as different from the synlactin 
activity described by Nicoll et al. (26), and has been named 
Liver Lactogenic Factor (LLF). 
The ontogeny and regulation of GH- and PRL-secreting 
cells are good examples of the complexity involved in 
endocrine systems. Multiple, seemingly redundant, and 
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sometimes contradictory (stimulatory as well as inhibitory) 
signals from the hypothalamus impinge upon the pituitary 
gland, which in itself is made up of a heterogeneous 
population of hormone secretors of a given type, to influ­
ence hormone release. To further complicate the matter, 
many protein hormones are known to actually represent a 
family of molecular variants with differing potencies and 
biological half-lives. In addition, the ratios of these 
variants (for FSH, ref. 27) in sera seem to change with the 
physiological state of the animal. Similarly, we now have 
reasonable evidence to suggest that functional interconver­
sion of hormone-secreting cell types may play an important 
role in the developmental and physiological regulation of 
endocrine processes. Finally, the discovery and study of 
molecules such as LLF and IGF-I may provide powerful insight 
into the mechanism and mode of action of polypeptide 
hormones such as PRL and GH, and help explain the diversity 
of functions ascribed to each of these hormones. The 
complex interplay of stimulatory and inhibitory factors as 
well as feedback effects of the hormones themselves and the 
regulation of the intermediate steps involved in hormone 
action all combine to produce an exquisite system of checks 
and balances which govern the process of homeostasis and 
perhaps life itself. Careful dissection of this endocrine 
code is a very tedious and formidable task, but it is now 
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possible due to the profusion of new technologies In 
cellular and molecular biology. 
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